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OPENING A CAN OF GENETICALLY-
MODIFIED WORMS:  FUNDING AND 
REGULATING CRISPR TECHNOLOGY 
I.  INTRODUCTION 
Recent advances in biotechnology have led to a revolutionary process 
in which scientists are able to edit the genes of an organism with 
unprecedented accuracy, speed, and affordability.1  This technological 
process can come from different gene-editing technologies such as 
CRISPR/Cas9 or CRISPR, which stands for Clustered Regularly 
Interspaced Short Palindromic Repeats.2  The potential benefits of CRISPR 
are expansive and could redirect how we treat genetic diseases.3  Of 
course, a powerful technology like CRISPR raises serious ethical questions 
about how it should and should not be used.4  While many agree that our 
society would benefit immeasurably from CRISPR, we must first ask 
ourselves how far we are willing to go to achieve such desired results.5  
                                                
1 See CRISPR Timeline, BROAD INSTITUTE https://www.broadinstitute.org/what-broad/ 
areas-focus/project-spotlight/crispr-timeline [https://perma.cc/ZAE2-ZESZ] (providing 
the timeline leading up through the advent of CRISPR).  The natural process of CRISPR was 
discovered in the early 1990s, but was not realized as a technological tool for scientists until 
2012.  Id.  Currently, CRISPR aims to cure a rare eye disease called Leber congenital 
amaurosis.  Id.  Antonio Regaledo, CRISPR Gene Editing to be Tested on People by 2017, MIT 
TECH. REV. (Nov. 5, 2015), https://www.technologyreview.com/s/543181/crispr-gene-
editing-to-be-tested-on-people-by-2017-says-editas/ [https://perma.cc/LS5E-PN29].  
Scientists are striving to cure a large variety of genetic diseases in the coming years and 
believe that a cure for cancer is not out of reach in the near future.  Id. 
2 See Martin Jinek et al., A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive 
Bacterial Immunity, 337 SCIENCE MAG. 816–21, http://science.sciencemag.org/content/337/ 
6096/816.full.pdf+html [https://perma.cc/THZ4-5LZX] (discussing the discovery of the 
CRISPR/Cas system discovery).  CRISPR stands for Clustered Regularly Interspaced Short 
Palindromic Repeats.  Id.  The process is an evolved adaptation in bacteria used to fight off 
viruses.  Id.  A deeper discussion on what CRISPR is and how it works will be discussed 
below.  See also infra Part II.B (discussing the process of gene editing through the use of 
CRISPR technology). 
3 See Thom Patterson, Unproven Medical Technique Could Save Countless Lives, Billions of 
Dollars, CNN (Oct. 30, 2015), http://www.cnn.com/2015/10/30/health/pioneers-crispr-
dna-genome-editing/ [http://perma.cc/Q7XC-3JWL] (describing the health and financial 
benefits CRISPR could bring to our society). 
4 See, e.g., Edward Lanphier et al., Don’t Edit the Human Germline, NATURE 
http://www.nature.com/news/don-t-edit-the-human-germ-line-1.17111 (Mar. 12, 2015), 
[htttp://perma.cc/MRW2-MHVW] (exemplifying one of many ethical concerns involving 
CRISPR).  The article discusses the most serious concerns involving permanent changes to 
human DNA.  Id. 
5 See Staff Reporter, GENOMEWEB https://www.genomeweb.com/gene-silencinggene-
editing/scientists-call-caution-use-crisprcas9-technology [http://perma.cc/5X6R-V3RX] 
(reporting the weighing tests scientists consider when acknowledging the benefits and 
consequences associated with CRISPR).  Scientists have called for transparency and 
standardized benchmarking in an attempt to curb concerns of human germline modification.  
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This Note aims to answer some of these questions by proposing new 
legislation that could be passed by Congress to help facilitate further 
research involving CRISPR, while also addressing many of the ethical 
concerns that have many fearful for the future direction of biosciences.6 
Part II of this Note outlines the background behind CRISPR by first 
briefly discussing the inception of CRISPR and how it is truly 
revolutionary in comparison to the technologies that came before it.7  Part 
II.B continues by explaining what CRISPR is, how it works, and the 
potential benefits of CRISPR as well as the relevant ethical considerations.8  
Part III analyzes the current law and balances the law with the current 
scientific and ethical discussions going on regarding CRISPR.9  Part III also 
explains why new legislation is not only necessary to address these 
problems, but also why legislation is the most effective and efficient way 
of doing so as opposed to alternative proposals.10  Part IV provides ethical 
boundaries and funding considerations that should be met with this 
legislation.11 
                                                
Id.  Human germline modification is the editing of genes of future generations of humans.  
About Human Germline Editing, CTR. FOR GENETICS AND SOC. (July 9, 2015), 
http://www.geneticsandsociety.org/article.php?id=8711 [http://perma.cc/BM5K-64HX]. 
“Human germline gene editing” or “human germline modification” 
means deliberately changing the genes passed on to children and future 
generations–in other words, creating genetically modified people.  
Human germline modification has for many years been widely 
considered off-limits, for both safety and social reasons.  It is formally 
prohibited in more than 40 countries. 
Id. 
6 See infra Part IV.A (proposing a piece of legislation to address multiple ethical and legal 
concerns associated with CRISPR, while also attempting to facilitate further research). 
7 See infra Part II.A (chronicling the advances in research that led to the discovery of 
CRISPR in bacteria and developing it into a tool). 
8 See infra Part II.B (discussing the revolutionary power of CRISPR and why it raises such 
urgent ethical and legal issues). 
9 See infra Part III (advocating for changes in the law, partially by repealing the Dickey-
Wicker Amendment that no longer accurately serves its original purpose). 
10 See infra Part III.B (explaining the unique advantages that naturally come with solving 
legal issues through new legislation). 
11 See infra Part IV (proposing a model act with narrowly tailored guidelines for directing 
federal funding toward CRISPR research).  This act aims to fund certain types of studies on 
CRISPR with the goal of being an investment in public health.  Id.  This proposed act 
proposes a repeal of the Dickey-Wicker Amendment, as discussed in Parts II and III.  Id.  
Next, the proposed act establishes a series of guidelines that specifically detail the types of 
studies that are funded by this act.  Id.  Additionally, the proposal specifies the types of 
research that are wholly prohibited, and what types of repercussions could follow if such a 
guideline is violated.  Id.  After the proposal is fully laid out, Part IV will continue by 
addressing a few anticipated reactions and arguments against this proposal.  Id.  These 
counter-arguments provided will involve the scope of the proposal and differentiating 
between the proposed act laid out below and recent developments in the law.  Id. 
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II.  BACKGROUND 
Gene editing is a practice that has been developing and has been 
theorized over the past few decades.12  “What used to be science fiction” 
has suddenly become a real part of modern science and medicine.13  Part 
II.A briefly traces the history of gene editing and its development up to 
this point.14  Next, Part II.B discusses what CRISPR/Cas9 is, how it works, 
and why it has changed the way we look at science and medicine.15  Part 
II.C touches on the ethical issues CRISPR raises and why these concerns 
should be immediately addressed by scientists, ethicists, and lawmakers.16  
Part II.D brings attention to the current legal issues that CRISPR is 
encountering as the full potential of CRISPR technology is being 
realized.17  A background on each of these subjects is necessary to consider 
the legal and ethical landscape ahead of us, and how lawmakers can most 
efficiently address these numerous issues.18 
A. Gene Editing and the Development of CRISPR 
Gene editing can be traced back to studies in the 1980s that looked to 
modify specific genes in mice.19  Shortly after that, gene-editing 
technologies, such as TALENs, were developed as efficient ways to 
modify an organism’s genes.20  The development of these technologies 
quickly accelerated after scientists successfully mapped the human 
                                                
12 See CRISPR Timeline, supra note 1 (tracing the theoretical discovery of a CRISPR system 
back to 1993 or earlier). 
13 See Jennifer Doudna, How CRISPR Lets Us Edit Our DNA, TED, at 11:55, 
https://www.ted.com/talks/jennifer_doudna_we_can_now_edit_our_dna_but_let_s_do_i
t_wisely?language=en [https://perma.cc/ZGN2-2C4Z] (suggesting that this subject could 
easily be seen as ridiculous because of its impossibility only a few years ago). 
14 See infra Part II.A (setting up the revolutionary nature of CRISPR). 
15 See infra Part II.B (explaining CRISPR in further detail to highlight why the technology 
is so controversial). 
16 See infra Part II.C (turning to the specific concerns scientists, ethicists, and lawmakers 
alike have regarding proceeding with further research involving CRISPR). 
17 See infra Part II.D (delving into issues raised by the Dickey-Wicker Amendment and 
Sherley v. Sebelius in the United States District Court of Washington D.C.). 
18 See infra Part IV (advocating for a remedy to these problems through new legislation). 
19 See Jon Chestnut, Analyzing TALEN v. CRISPR, GENETIC ENG’G & BIOTECHNOLOGY 
NEWS (Oct. 13, 2016), http://www.genengnews.com/gen-exclusives/analyzing-talen-vs-
crispr/77900759 [https://perma.cc/P83U-LYVX] (mentioning a brief description of early 
gene-editing research in the 1980s conducted on mice). 
20  See id. (explaining TALENs as an alternative gene-editing method that is highly 
accurate, but lacks the “simplicity and versatility of CRISPR”).  TALENs stands for 
Transcription Activator-Like Effector Nucleases.  Id.  One clear advantage is that TALENs is 
licensed for commercial use.  Id.  CRISPR is still in a bitter patent dispute, which maintains a 
level of uncertainty with its availability for commercial use in the very-near future.  Id. 
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genome in 2003.21  But, it wasn’t until 2012 when Professor Jennifer 
Doudna and her colleagues at the University of California, Berkeley 
discovered a breakthrough technology now known as CRISPR/Cas9 (or 
CRISPR) in bacteria.22 
Before the development of CRISPR, the process of editing genes was 
an arduous process that would cost thousands of dollars for each use and 
could have taken weeks or months to achieve a desired result.23  Even 
then, the results lacked accuracy—which is a great concern in the business 
of changing an organism’s genes.24  Now CRISPR has provided an 
exponentially faster method of altering DNA.25  Additionally, the cost of 
a single use of the technology has been reduced to about $75 per use.26  On 
top of the increased affordability and speed of the gene-editing 
technology, CRISPR has improved accuracy of the desired result 
tremendously.27 
                                                
21  See Human Genome Project, NAT. INST. OF HEALTH, https://report.nih.gov/ 
nihfactsheets/ViewFactSheet.aspx?csid=45 [https://perma.cc/M7MG-86LF] (chronicling 
the human genome project and what has resulted from the project’s completion).  Notably, 
over “1,800 disease genes” have been discovered.  Id. 
22 See Jinek et al., supra note 2, at 816–21 (presenting the discovery of the CRISPR system 
in bacteria).  The naturally occurring CRISPR system was discovered as a result of evolution 
in bacteria.  Id.  It is the process by which bacteria fights off viruses, similarly to the way a 
vaccine works in patients.  Id.  A bacteria cell is able to record or “take a snapshot” of the 
virus DNA so that the next time the bacteria encounters a virus with that DNA, it will be 
able to efficiently attack that virus through its recognition recorded by CRISPR.  Id.  This 
Note references Jennifer Doudna as the discovering part of the CRISPR technology (as she 
has been represented in the media), but this could be disputed.  Broad Inst., Junior Party v. 
The Regents of The University of Cal., Patent Interference No. 106,048 (P.T.A.B., Feb. 15, 
2017).  Doudna and her team lost the first stage of the CRISPR patent dispute in early 2017, 
which will likely continue through several rounds of appeals.  Id. 
23  See generally Jim Yeadon, Pros and Cons of ZNFs, TALENs, and CRISPR/Cas, JACKSON LAB. 
(Mar. 4, 2016), https://www.jax.org/news-and-insights/jax-blog/2014/march/pros-and-
cons-of-znfs-talens-and-crispr-cas# [https://perma.cc/QK63-UB4D] (discussing Zinc 
Finger Nucleases (ZFN or ZNF) and TALENs as alternatives to earlier gene-editing 
technologies).  While both technologies are still used and have their advantages, both have 
been overshadowed by CRISPR’s abilities.  Id. 
24 See generally id. (describing how CRISPR is far more economically feasible and far more 
accurate). 
25 See id. (listing differences between CRISPR, TALENs, and ZNFs).  See, e.g., Overview, 
INTELLIA THERAPEUTICS (last visited Sept. 3, 2017), http://www.intelliatx.com/about-
us/overview/ [https://perma.cc/MV9G-6RH7] (describing the company as a “leading 
genome editing company”).  Intellia was founded by co-inventor of CRISPR, Jennifer 
Doudna.  Id.  See also, Company Overview, EDITAS MEDICINE (last visited Sept. 3, 2017), 
http://www.editasmedicine.com/company-overview [https://perma.cc/6HJF-5NWJ] 
(presenting itself as another “leading genome editing company”). 
26 See generally Yeadon, supra note 23 (noting how previous gene-editing techniques could 
take “2-3 years to complete and could cost up to $100,000”). 
27 See generally Yeadon, supra note 23 (explaining CRISPR’s ability to target specific genes 
to change or delete). 
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B. How CRISPR Works and Why it is a Game-Changer 
CRISPR’s revolutionary ability is derived from a naturally occurring 
process in human immune systems, whereby proteins can recognize 
foreign organisms such as viruses.28  The proteins then work with the 
DNA to take a “snapshot” of this potentially harmful organism so that the 
cell may recognize it again at a later time and know how to attack it, 
thereby eliminating the virus from the body.29  Scientists have learned to 
influence this process by using the Cas9 protein to first locate a specific 
sequence in an organism’s DNA.30  After the desired sequence is 
identified, the protein is then able to “cut out” the selected sequence and 
replace it with an entirely new DNA sequence.31  As a result, this changes 
one of the organism’s natural traits.32 
In the naturally occurring version of this process, DNA is altered to 
build immunity to foreign and possibly harmful organisms like viruses.33  
With CRISPR, the intentional alteration of DNA may come with a wide 
range of goals.34  Some of these goals are more practical, while others are 
                                                
28 See Jinek et al., supra note 2, at 816–21 (recounting the discovery which first occurred in 
bacteria cells, where the bacteria cells use RNA to record a genetic “snapshot” of the virus in 
order for the cell to better protect itself against future viral attacks). 
29 See Doudna, supra note 13, at 00:33 (analogizing the CRISPR process to a human 
immune system). 
30 See Jinek et al., supra note 2, at 820 (explaining how scientists may harness this process 
and manipulate it to target specific genes). 
31 See Jinek et al., supra note 2, at 816 (illustrating how RNA strands are guided by the Cas9 
protein to read and identify specific genes). 
32 See Genes, MERRIAM-WEBSTER (last visited Sept. 3, 2017), http://www.merriam-
webster.com/dictionary/gene [https://perma.cc/VZV4-HQTM] (providing a definition of 
“gene” as a part of a cell that controls or influences the appearance, growth, etc. of a living 
thing).  A more specific definition provides: 
A specific sequence of nucleotides in DNA or RNA that is located 
usually on a chromosome and that is the functional unit of inheritance 
controlling the transmission and expression of one or more traits by 
specifying the structure of a particular polypeptide and especially a 
protein or controlling the function of other genetic material. 
Id.  See also Traits, MERRIAM-WEBSTER (last visited Sept. 3, 2017), http://www.merriam-
webster.com/dictionary/trait [https://perma.cc/DPX7-V5MR] (describing a trait as “a 
quality that makes one person or thing different from another”). 
33 See Jinek et al., supra note 2, at 820 (providing the conclusions reached by the study). 
34 See Antonio Regalado, Engineering the Perfect Baby, MIT TECH. REV. (Mar. 5, 2015), 
https://www.technologyreview.com/s/535661/engineering-the-perfect-baby/ 
[https://perma.cc/YLA7-SCYX] (providing the wide-ranging potential of CRISPR).  
Purposes range from medical to cosmetic.  Id.  Some scientists aspire to bring back extinct 
species, while others aim to cure diseases or solve world hunger.  Id.  While other uses may 
have an impact on public health, such as using CRISPR on crops to combat world hunger or 
to increase the health benefits of certain foods, those issues are outside the scope of this 
discussion.  Id.  The use of CRISPR to combat diseases spread by animals is also outside the 
scope of this Note.  Id.  Using CRISPR on viable human embryos that will eventually develop 
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more theoretical for the time being (even though the technology’s ability 
already exists).35  Of the more immediately practical uses, some scientists 
see value in using CRISPR to alter crops in a variety of ways, such as 
combatting world hunger, or climate change by developing food that can 
grow in a changing climate, as well as herbicide resistant crops.36  Using 
CRISPR on animals also has potential value in a more narrow sense.37  
Altering the DNA of mosquitoes so that they are incapable of carrying the 
West Nile or Zika viruses is an example that provides humans with 
advantages in eradicating diseases.38  However, the most popular 
proposed use of CRISPR involves human application to treat and cure 
various human ailments.39  The medical application of CRISPR is likely 
                                                
into a person will not be permitted with this act.  Id.  The concerns involving cost of CRISPR 
treatments are too skeptical at this point in time and the relevant problems are still not 
entirely tangible.  Id.  Finally, theoretical uses including resurrecting extinct species will not 
be discussed.  Id. These exclusions are not intended to rule on the merits of those scientific 
goals, but to restrict this act to aid the issues most immediately of concern to the American 
public.  Id.  It is not out of the question for these excluded issues to still be addressed in this 
act, but for the purpose of having a narrowly tailored goal, they will be regarded as outside 
the scope of consideration.  Id. 
35 See generally Abumrad & Krulwich, http://www.radiolab.org/story/antibodies-part-
1-crispr/ [https://perma.cc/3JQA-EPJ2] (recounting an earlier conversation between one of 
the hosts and an anonymous scientist familiar with CRISPR). While the scientific value of 
changing a Golden Retriever into a Great Dane likely does not exist, scientists claim to 
already have the power to do so with CRISPR.  Id.  Using DNA found from Wooly Mammoth 
hair could be inserted into an elephant embryo and it could develop into a fully grown, living 
Wooly Mammoth.  Id. 
36 See Maywa Montenegro, CRISPR is Coming to Agriculture–With Big Implications for Food, 
Farmers, Consumers, and Nature, ENSIA (Jan. 28, 2016), http://ensia.com/voices/crispr-is-
coming-to-agriculture-with-big-implications-for-food-farmers-consumers-and-nature/ 
[https://perma.cc/SD59-BSAR] (stating the intended uses of CRISPR in agriculture range 
from “crop resistance to pests to livestock disease”).  See also Alison Peck, The Failure of Federal 
Biotechnology Regulation, 51 VAL. U. L. REV. 483, 510 (2017) (describing the use of CRISPR in 
crops). 
37 See generally id. (discussing various attempts made to address problems related to 
livestock diseases and production). 
38  See id. (explaining the highly controversial idea of using CRISPR to sterilize the roughly 
thirty species of mosquitoes that carry malaria, effectively driving them to extinction).  This 
can be done by using CRISPR on viable mosquito embryos.  Id.  This type of change (as 
opposed to a change to an adult mosquito) would be naturally passed down to that 
mosquito’s offspring, thereby permanently changing the mosquito’s genome.  Id.  Issues 
involving altering the DNA of viable human embryos and altering the human germline are 
the primary ethical issues linked to CRISPR, both of which will be discussed later.  See also 
infra Part II.C (providing information on germline editing); infra Part III (discussing aspects 
of the law and their effect on CRISPR). 
39 See generally Patterson, supra note 3 (noting the specific plans to go after genes linked to 
obesity and Alzheimer’s). 
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the most immediate potential use of CRISPR, as scientists are already 
beginning human trials on a small scale.40 
Scientists and medical experts alike are thrilled with the prospect of 
treating or even curing diseases such as Alzheimer’s, to other genetic 
diseases from muscular dystrophy to rare forms of blindness.41  The first 
studies that research the human application of CRISPR are underway in 
other countries, while the first clinical trial here in the United States was 
approved by a federal ethics panel in June of 2016.42  However, the ethical 
concerns involved with CRISPR are many in number and are the primary 
reason why research has slowed for the time being.43 
C. Ethical Considerations Linked to CRISPR 
Despite the possible benefits of curing many of the diseases that have 
plagued humanity for centuries, many scientists, ethicists, and lawmakers 
believe that we should seriously consider how far we are willing to go in 
order to achieve such results.44  If humans have the power to alter the 
                                                
40 See generally Patterson, supra note 3 (implying that CRISPR will not be raising extinct 
species in the near-future).  See also Emily Mullin, Gene Editing Study in Human Embryos Points 
Toward Clinical Trials, MIT TECH. REV. (Aug. 2, 2017), https://www.technologyreview.com/ 
s/608482/gene-editing-study-in-human-embryos-points-toward-clinical-trials/ 
[https://perma.cc/TSU3-768T] (discussing one of the most recent studies using CRISPR). 
41 See Megan Thielking, Using CRISPR to Edit Out Blindness, STAT (Jan. 27, 2016), 
https://www.statnews.com/2016/01/27/crispr-gene-editing-blindness/ 
[https://perma.cc/682T-6JR9] (reporting on the ability to create retinal cells using CRISPR 
and to transplant them into a patient experiencing blindness due to a genetic mutation). 
42 See Sharon Begley, Federal Panel Approves First Use of CRISPR in Humans, STAT (June 21, 
2016), https://www.statnews.com/2016/06/21/crispr-human-trials/ [https://perma.cc/ 
QW9Y-Q9KC] (discussing a proposed study that would use CRISPR to “alter immune cells 
to attack three kinds of cancer”).  The National Institutes of Health’s Recombinant DNA 
Advisory Committee (RAC) approved the study unanimously.  Id.  The study will be the first 
clinical trial in the United States and will test the safety of the human application of CRISPR.  
Id.  Studies such as this are precisely the type this proposed legislation aims to encourage 
and make more common.  See also Mullin, supra note 40 (discussing a groundbreaking study 
involving human embryos); infra Part III.D (reflecting CRISPR’s progress through current 
and proposed studies). 
43 See generally Abumrad & Krulwich, supra note 35 (saying that the term moratorium is 
perhaps too severe in light of remaining goals to continue CRISPR research).  See also 
Doudna, supra note 13 (asking for a temporary “moratorium” on the use of CRISPR in 
embryos).  Doudna cites to “recent precedent” for such a temporary moratorium, as 
molecular cloning became possible in the late 1970s.  Id. 
44 See Genetically Engineered Human DNA: Hearing before the Subcomm. on Research and 
Technology of the H. Comm. on Science, Space, and Technology, 114th Cong. (2015) (statement of 
Jeffrey P. Kahn) http://congressional.proquest.com.ezproxy.valpo.edu/congressional/ 
result/congressional/pqpdocumentview?accountid=14811&groupid=95261&pgId=687815
76-d0a2-4cc3-90e2-5799ae98f525&rsId=1577698A153 [https://perma.cc/P6GR-V8PD] 
(testifying to the importance of establishing an ethical framework for how to approach 
CRISPR). 
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DNA of their own species, what would keep them from using that ability 
frivolously or to disadvantage certain classes of people?45  This does not 
exclude Jennifer Doudna, CRISPR’s co-creator.46  She believes that 
permanently altering the human germline is an irresponsible and 
dangerous step to take at this point in time.47 
This ethical concern largely involves the use of CRISPR on viable 
human embryos.48  If changes are made to the DNA of a human embryo 
that will eventually grow into a living person, those alterations are not 
only permanent, but will be passed on to the individual’s offspring.49  This 
is what scientists call “editing the human germline.”50  Editing the human 
germline irreversibly changes the natural path of human evolution and 
essentially puts humans in control of their own future, taking it out of 
nature’s hands.51 
                                                
45 See generally Anna Louise Sussman, Burden of Healthcare Costs Shifting to the Middle Class, 
THE WALL STREET JOURNAL (Aug. 25, 2016), http://www.wsj.com/articles/burden-of-
health-care-costs-moves-to-the-middle-class-1472166246 [https://perma.cc/KK94-H65H] 
(discussing the general burdens of health care costs and how they are disproportionately 
harming the middle class). 
46 See Abumrad & Krulwich, supra note 35 (calling for a temporary moratorium on using 
CRISPR).  Jennifer Doudna states that CRISPR is not yet ready for human application, 
primarily because of a lack of success in a Chinese study done on unviable human embryos.  
Id. 
47 See Abumrad & Krulwich, supra note 35 (noting specifically the permanent effect of 
editing the human germline). 
48 See generally Ewen Callaway, Second Chinese Team Reports Gene Editing in Human 
Embryos, NATURE (Apr. 8, 2016), http://www.nature.com/news/second-chinese-team-
reports-gene-editing-in-human-embryos-1.19718 [https://perma.cc/CQ3Y-9PQB] 
(reporting on a Chinese study which used unviable human embryos).  While the article notes 
remaining controversy; in using unviable embryos, it clarifies that no viable embryos were 
used, emphasizing what a wholly unethical step it could have been.  Id. 
49 See Patrick Skerrett, A Debate: Should We Edit the Human Germline?, STAT (Nov. 30, 2015), 
https://www.statnews.com/2015/11/30/gene-editing-crispr-germline/ 
[https://perma.cc/T7YH-U2VT] (discussing the risks associated with editing the human 
germline).  See also Jeff Delviscio, NIH Director Francis Collins to Stay on, At Least for Now, 
Under Trump, STAT (Jan. 19, 2017), https://www.statnews.com/2017/01/19/francis-
collins-nih-donald-trump/ [https://perma.cc/Y5BG-5NMH].  President Trump has 
retained Collins for now, but the director may not be kept on for a full term.  Id. 
50 See id. (describing germline editing).  Francis Collins states that “medical research 
should always seek to balance benefits and risks.”  Id. 
51 See Skerrett, supra note 49 (explaining the nature of germline editing).  George Church 
asks what we should consider improvements in the human germline.  Id.  This work can be 
done through the use of gene drives.  See also Brooke Borel, When Evolution Fights Back Against 
Genetic Engineering, THE ATLANTIC (Sept. 12, 2016), https://www.theatlantic.com/science/ 
archive/2016/09/gene-drives/499574/ [https://perma.cc/DA8C-AU87].  The use of gene 
drives is a process that is essentially a “forced succession” of a trait.  Id.  This process has 
already been successfully executed on fruit flies in a lab setting.  Id.  However, scientists 
disagree as to how a gene drive would play out in the wild, should it ever occur.  Id.  They 
may be just as likely to destroy a species as they are to save or alter one.  Id. 
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Since the inception of in vitro fertilization (IVF), people have had the 
ability to choose the sex of their child, as well as their eye or hair color.52  
However, CRISPR raises new issues in this respect.53  The accuracy, ease 
of use, and affordability of CRISPR leads many to wonder what would 
prevent parents from increasing the intelligence of their child or making 
them more physically gifted.54  Using CRISPR with the goals of changing 
the appearance, strength, or intelligence of future generations is a major 
concern of many.55  The idea of genetically engineered humans to this 
degree still sounds like science fiction, but the issue caught the attention 
of the MIT Technology Review enough to warrant a cover story in 2015 on 
exactly this issue.56  While arguably speculative, the next logical concern 
is the potentially increased costs of these types of procedures, which 
would lead to only the higher economic classes having access, 
disadvantaging the majority of Americans.57 
                                                
52 See Emily Singer, Choosing Babies, MIT TECH. REV. (Mar. 1, 2007), 
https://www.technologyreview.com/s/407398/choosing-babies/ [https://perma.cc/ 
76LY-JCGN] (reporting how parents frequently use in vitro fertilization to choose the sex of 
their child). 
53 See id. (speculating that parents may someday be choosing the IQ of their child).  See 
also Regalado, supra note 34 (discussing the present concern of CRISPR’s future ability to 
control an embryo’s genes that control intelligence). 
54 See Regalado, supra note 34 (explaining the numerous types of genetic alterations that 
could be made to a child during the prenatal stages of development). 
55 See id. (discussing the more theoretical, but scientifically possible future uses of CRISPR 
which concern many scientists).  These concerns include permanent changes to the human 
genome.  Id.  There are also slippery slope arguments pertaining to somatic gene therapy.  
See also Tony McGleenan, Human Gene Therapy and Slippery Slope Arguments, 21 J. OF MEDICAL 
ETHICS, 350–55 (1995).  Somatic gene therapy includes gene therapy where DNA changes are 
not passed down to further generations.  Id.  These arguments could potentially be carried 
over to germline editing discussions.  Id.  These arguments can be classified as logical 
slippery slope arguments and rhetorical slippery slope arguments.  Id.  However, “with 
unambiguous legislation logical slippery slope arguments have little or no force.”  Id.  These 
arguments mostly become relevant when regulation is on the table.  Id.  When it comes to 
rhetorical slippery slope arguments, the flaws can often be resolved with close analysis.  Id.  
This is because the rhetorical slippery slope arguments often present larger leaps in logic.  Id. 
56 See Regalado, supra note 34 (noting CRISPR’s capabilities rather than its current uses).  
See also generally McGleenan, supra note 55 (inferring that this concern falls in line with a 
logical slippery slope argument that the legalization of germ line editing could lead to 
designer babies). 
57 See generally David Warmflash, Gene Therapy 2.0:  Will CRISPR Make Expensive Treatment 
Accessible to All?, GENETIC LITERACY PROJECT (Aug. 16, 2016), 
https://www.geneticliteracyproject.org/2016/08/16/gene-therapy-2-0-will-crispr-make-
expensive-treatment-accessible/ [https://perma.cc/HBE2-ZCTD] (noting current gene 
therapy treatments to cost around $1,000,000). 
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D. Legal Implications 
The problems CRISPR is encountering in regards to federal funding 
begin with The Dickey-Wicker Amendment, and therefore, this discussion 
must logically begin there.58  Discussing what The Dickey-Wicker 
Amendment was intended for, and how it has been interpreted, is critical 
to understanding the problem and the appropriate remedy for CRISPR to 
attain federal funding.59  Part II.D.1 discusses the ethical scope of the 
Dickey-Wicker Amendment and its implications related to CRISPR.60  
Next, Part II.D.2 discusses how Sherley v. Sebelius could affect CRISPR 
going forward.61 Together, this legal and ethical background and analysis 
will provide a sufficient basis for the introduction of new legislation.62  The 
ultimate goal of this section is to examine the original purposes of the 
Dickey-Wicker Amendment and analyze the interpretations of the 
Dickey-Wicker Amendment.63  The effects of the Dickey-Wicker 
Amendment on the National Institutes of Health (NIH) have prevented 
them from funding promising advances in science such as CRISPR.64 
1. The Dickey-Wicker Amendment 
In 1996 a bill that would become the “The Balanced Budget Down 
Payment Act of 1996” was introduced in the U.S. House of 
Representatives.65  The text of Section 128 of this bill would become known 
                                                
58 See infra Part II.D.1 (discussing the Dickey-Wicker Amendment). 
59 See infra Part II.D.2 (analyzing the Sherley v. Sebelius case). 
60 See infra Part II.D.1 (examining the shifting ethical considerations associated with the 
Dickey-Wicker Amendment).  See also Part III.B (analyzing various proposals). 
61 See infra Part II.D.2 (discussing the effect of Sherley v. Sebelius on CRISPR). 
62 See infra Part III (proposing new legislation). 
63 See infra Part II (discussing, generally, the implications of the Dickey-Wicker 
Amendment). 
64 See Francis S. Collins, Statement on NIH Funding of Research Using Gene-Editing 
Technologies in Human Embryos, NATIONAL INSTITUTES OF HEALTH (Apr. 29, 2015), 
https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-
funding-research-using-gene-editing-technologies-human-embryos 
[https://perma.cc/93FU-P8AJ] (exemplifying the impact of the Dickey-Wicker Amendment 
in 2015).  “Practically, there are multiple existing legislative and regulatory prohibitions 
against this kind of work.”  Id.  “The Dickey-Wicker amendment prohibits the use of 
appropriated funds for the creation of human embryos for research purposes or for research 
in which human embryos are destroyed.”  Id. 
65 See The Balanced Budget Downpayment Act, Pub. L. No. 104–99, § 128, 110 Stat. 34 
(1996) [hereinafter The Balanced Budget Downpayment Act] (providing original text of the 
bill). The name of the amendment comes from the sponsors of the amendment, 
Representative Jay Dickey of Arkansas’ 4th District and now-Senator Roger Wicker of 
Mississippi’s 1st District.  Id.  This was one section of a larger appropriations bill pertaining 
to the Departments of Interior, Labor, Health and Human Services, and Education.  Id. 
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as the Dickey-Wicker Amendment in subsequent budget acts.66  The 
amendment states: 
None of the funds made available by Public Law 104–91 
may be used for— 
(1) the creation of a human embryo or embryos for 
research purposes; or 
(2) research in which a human embryo or embryos are 
destroyed, discarded, or knowingly subjected to risk of 
injury or death greater than that allowed for research on 
fetuses in utero under 45 CFR 46.208(a)(2) and 42 U.S.C. 
289g(b).67 
At the time, Congressional opposition described the amendment as 
pro-life opposition to IVF.68  What is certain is that the Dickey-Wicker 
Amendment arose out of concern over IVF.69  The language of the law 
explicitly prohibits federal funding to be applied to research on human 
embryos.70  This broad language does not discern between viable and 
unviable embryos; it appears more as a blanket prohibition.71 
                                                
66 See id. (giving the language of The Dickey-Wicker Amendment as it appears in 
subsequent budget acts). The amendment provides that: 
(a) None of the funds made available in this act may be used for—(1) 
the creation of a human embryo or embryos for research purposes;  
or (2) research in which a human embryo or embryos are 
destroyed, discarded, or knowingly subjected to risk of injury or 
death greater than that allowed for research on fetuses in utero 
under 45 CF.R. 46.208(a)(2) and section 498(b) of the Public Health 
Service Act (42 U.S.C. 289g(b)).  (b) For purposes of this section, the 
term “human embryo or embryos” include any organism, not 
protected as a human subject under 45 CF.R. 46 as of the date of the 
enactment of this Act, that is derived by fertilization, 
parthenogenesis, cloning, or any other means from one or more 
human gametes or diploid cells. 
Id. 
67 See id. (providing the original language of the Dickey-Wicker Amendment). 
68 See 142 Cong. Rec. 16,866 (1996) (debating the merits of conflicting amendments).  
Whether the amendment was pro-life is debatable and irrelevant to this Note.  Id. 
69 See generally Ann A. Kiessling, The History of the Dickey-Wicker Amendment, BEDFORD 
RESEARCH FOUNDATION (Aug. 24, 2010), http://archive.is/vjHtK [https://perma.cc/2B67-
3V5G] (discussing the introduction of the Dickey-Wicker Amendment in light of the in vitro 
fertilization and “test tube baby” debates). 
70 See The Balanced Budget Downpayment Act, supra notes 65–66 (citing to the language 
of the bill). 
71 See id. (citing to the language of the bill). 
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Of course, a bill restricting research in the field of biotechnology was 
sure to become outdated relatively quickly.72  The amendment has had 
unintended consequences as science has progressed over the past two 
decades.73  The National Institutes of Health—the primary government 
agency that awards research grants to medical studies across the 
country—has identified this problem as one of the main reasons why they 
will not fund gene-editing research.74  Attempts have been made to 
eliminate or overturn the Dickey-Wicker Amendment, but those attempts 
have been unsuccessful as they lack legislative action.75  An Executive 
Order from President Obama in 2009 gave the NIH permission to fund 
embryonic stem cell research.76  This order required the NIH to establish 
new guidelines for how the organization approaches stem cell research.77  
Dickey-Wicker’s continuing impact can be felt to this day, as the 
amendment has been included in every omnibus spending bill since the 
Dickey-Wicker Amendment was enacted.78  Additionally, the United 
States Court of Appeals weighed in on how the NIH should interpret the 
Dickey-Wicker Amendment in Sherley v. Sebelius.79 
                                                
72 See Sherley v. Sebelius, 689 F.3d 776, 779 (D.C. Cir. 2012) (describing the rapid advance 
of stem cell research capabilities shortly after the initial enactment of the Dickey-Wicker 
Amendment).  At the time the Dickey-Wicker Amendment was drafted, germ line editing 
was not scientifically feasible.  See also McGleenan, supra note 55 (reflecting the progress of 
gene editing in the 1990s).  Cf. Sharon Begley, Scientists Solve CRISPR’s ‘Energizer Bunny’ 
Problem, STAT (Apr. 27, 2016), https://www.statnews.com/2016/04/27/crispr-energizer-
bunny-problem/ [https://perma.cc/L8A6-EE84] (exemplifying the rapid advances of 
biotechnology, especially with CRISPR).   
73 See Collins, supra note 64 (exemplifying the impact of the Dickey-Wicker Amendment 
in 2015). 
74 See Collins, supra note 64 (stating the National Institutes of Health stance on awarding 
grants to gene-editing research with the Dickey-Wicker Amendment still in place). 
75 See, e.g., Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (allowing the NIH 
to conduct and fund research on human embryos to the extent of the law, but the extent of 
the law is where the Dickey-Wicker Amendment begins). 
76 See id. (addressing the issue of embryonic research as it pertains to the stem cell research 
controversy). 
77 See 74 Fed. Reg. 32,170 (July 7, 2009) (describing the guidelines).  See also Sherley, 689 
F.3d at 780 (discussing the new NIH guidelines as they apply to the Dickey-Wicker 
Amendment in the facts of the case). 
78 See, e.g., The Balanced Budget Downpayment Act, supra notes 65–66 (exemplifying the 
continued presence of the amendment the 2015 budget). 
79 See Sherley, 644 F.3d at 390 (discussing President Obama’s Executive Order and its effect 
on the interpretation of the Dickey-Wicker Amendment).  The Supreme Court discusses the 
history of the Dickey-Wicker Amendment in more detail: 
In 1996, when the Congress first passed Dickey–Wicker, scientists had 
taken steps to isolate ESCs but had not yet been able to stabilize them 
for research in the laboratory.  The historical record suggests the 
Congress passed the Amendment chiefly to preclude President Clinton 
from acting upon an NIH report recommending federal funding for 
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2. Sherley v. Sebelius & The National Institutes of Health 
Sherley v. Sebelius arose out of dispute about NIH guidelines that were 
mandated by an executive order from President Obama in 2009.80  Prior to 
this proclamation, President Bush had also issued an executive order 
permitting stem cell research in a very restricted manner.81  Scientific 
advances in the years following the creation of the Dickey-Wicker 
Amendment led to President Obama’s proclamation allowing the NIH to 
support stem cell research “to the extent permitted by law.”82  It is this 
executive order that led to the dispute in Sherley.83  The guidelines 
required in President Obama’s executive order provided stem cell 
researchers with fewer restrictions in their work.84  Accordingly, the 
appellant brought the action after its concerns went unaddressed during 
the comment period.85 
In the Sherley court’s analysis the interpretation of the term “research” 
in the Dickey-Wicker Amendment was deemed ambiguous, which sided 
                                                
research using embryos that had been created for the purpose of in vitro 
fertilization. Dickey–Wicker became directly relevant to ESCs only in 
1998, when researchers at the University of Wisconsin succeeded in 
generating a stable line of ESCs, which they made available to 
investigators who might apply for NIH funding. 
 For that reason, on January 15, 1999, the General Counsel of the 
Department of Health and Human Services issued a memorandum 
addressing whether Dickey–Wicker permits federal funding of research 
using ESCs that had been derived before the funded project began; she 
concluded such funding is permissible because ESCs are not “embryos.” 
After notice and comment, the NIH issued funding guidelines 
consistent with this opinion, but the NIH did not fund any ESC research 
project while President Clinton was in office. 
Id. 
80 See id. at 779–80 (discussing executive orders issued by President George W. Bush and 
President Obama). See also Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) 
(providing the original language of the executive order). 
81 See Sherley, 644 F.3d at 779–80 (giving a brief background that led to the case at bar).  See 
also Proclamation No. 13,435, 72 Fed. Reg. 34,591 (June 27, 2007) (showing the scope of 
President Bush’s executive order). 
82 See Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (quoting the language of 
the 2009 executive order). 
83 See Sherley, 644 F.3d at 779–80 (discussing the background of the case). 
84 See id. at 780 (citing to the executive order).  The guidelines state the following: 
Embryonic stem cell research project may receive NIH funding as long 
as it utilizes cells from lines (1) created by in vitro fertilization for 
reproductive purposes, (2) no longer needed for that purpose, and (3) 
voluntarily donated by the individuals who owned them—even if that 
line was derived after 2001). 
Id. 
85 See id. (discussing the original cause of action in the case). 
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with the NIH’s interpretation.86  By applying Chevron deference to the 
NIH’s interpretation of the Dickey-Wicker Amendment, the court held 
that it was reasonable to interpret the “term ‘research’ as a discrete project 
rather than an extended process.”87  As a result of this decision, the 
destruction of embryos as part of the embryonic stem cell derivation 
process was not a part of the funded research project, and therefore no 
violation of the Dickey-Wicker Amendment existed.88  Additionally, the 
court saw these enacted guidelines allowing for the funding of stem cell 
research as following the triggering executive order.89  However, this 
funding of stem cell research would not have been possible without the 
two executive orders mentioned above, which specifically endorse stem 
cell research to different extents.90 
                                                
86 See id. at 783 (applying the Chevron deference).  The appellants in this case were 
scientists objecting to the funding of any kind of stem cell research.  Id.  Specifically, the 
group was opposed to the guidelines set out in President Obama’s executive order allowing 
stem cell research to the extent allowed by law.  Id.  The appellants sought an injunction 
against the NIH to halt the funding of any embryonic stem cell research despite President 
Bush’s executive order allowing such funding for ten years.  Id.  The appellants’ argument 
raised three main issues.  Id.  First, that the guidelines being implemented violated the 
language of the Dickey-Wicker Amendment prohibiting funding for “research in which a 
human embryo or embryos are destroyed.”  Id.  Second, that in the alternative, the guidelines 
violate the language prohibiting research where human embryos are “subjected to risk of 
injury or death greater than that allowed for research on fetuses in utero.”  Id.  Finally, 
appellants argued that the failure to respond to objecting comments during the regulation’s 
comment period.  Id.  The Court discounted all three arguments by applying Chevron 
deference to the NIH’s interpretation of the executive order, and that the NIH has no duty 
to respond to objections before the regulation is enacted.  Id. 
87 See Sherley, 689 F.3d at 783 (explaining how the NIH made a reasonable interpretation 
of the term “research” as ambiguous); Chevron, U.S.A., Inc. v. Natural Resources Defense 
Council, Inc., 467 U.S. 837, 865 (1984).  Further, Justice Stevens states: 
An agency to which Congress has delegated policy-making 
responsibilities may, within the limits of that delegation, properly rely 
upon the incumbent administration’s views of wise policy to inform its 
judgments.  While agencies are not directly accountable to the people, 
the Chief Executive is, and it is entirely appropriate for this political 
branch of government to make such policy choices—resolving the 
competing interests which Congress itself either inadvertently did not 
resolve, or intentionally left to be resolved by the agency. 
Id.  See Sherley, 689 F.3d at 785–87 (plurality opinion) (discussing how the concurring opinion 
disagrees with the applicability of Chevron deference to executive orders).  Judge Henderson 
believes that it only applies to legislative material coming from Congress.  Id.  Chevron 
deference provides administrative agencies the ability to resolve ambiguity in the language 
of a law.  Id. 
88 See Sherley, 689 F.3d at 783–84 (explaining how the funded research projects did not 
destroy human embryos or subject them to risk). 
89 See id. at 785 (addressing the failure to reply to comments during the set time period 
while the proposed change is made public). 
90 See generally Consolidated Appropriations Act of 1996, Pub. L. No. 104-99, 110 Stat. 26, 
34 (providing the language of the Dickey-Wicker Amendment preventing this type of 
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3. Applicability to CRISPR 
At this time, there is no such executive order or legislation that 
specifically allows for the federal funding of research related to CRISPR.91  
As a result, the Dickey-Wicker Amendment still bars the NIH from 
becoming involved with CRISPR.92  In Sherley, executive orders react to 
the progress of science.93  What is also evident is that these executive 
orders were necessary to bypass the Dickey-Wicker Amendment.94  Since 
the discovery of the CRISPR technology in 2012, no such executive orders 
or legislation have been enacted relating to CRISPR.95  However, some 
pieces of proposed legislation have come forward in 2017.96 
Twenty years ago, long before the conception of CRISPR, lawmakers 
recognized the problems involved with banning federal funding of stem 
cell research.97  In 1996, there was support for the “Lowey Amendment,” 
which would have overturned the Dickey-Wicker Amendment and 
restored the federal government’s ability to fund embryonic stem cell 
research.98  This amendment would have served as an appropriations bill 
“rider,” rather than an independent bill.99  Ultimately, the arguments in 
                                                
research). The court’s application of Chevron and the two executive orders gave the NIH 
freedom to fund stem cell research.  See also Sherley, 644 F.3d at 390.  CRISPR lacks such an 
executive order or legislation permitting federal funds to go towards CRISPR research 
specifically.  Cf. id.  But The Dickey-Wicker Amendment is still good law.  Id. 
91 See Chestnut, supra note 19 (discussing the Dickey-Wicker Amendment’s bar on federal 
funds going toward germ line editing). 
92 See id. (implying the need for a new law allowing for the allocation of federal funds for 
CRISPR research). 
93 See Sherley, 644 F.3d at 390 (discussing the purpose of the two executive orders). 
94 See Proclamation No. 13,435, supra note 82 (addressing recent advances in stem cell 
research that had occurred shortly after the Dickey-Wicker Amendment was first enacted).  
See also Proclamation No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009) (reacting to further 
progress in stem cell research). 
95 See generally Collins, supra note 64 (illustrating the need for changes in the law). 
96 See e.g., H.R. 2921, 114th Cong. (2015) (exemplifying proposed legislation that intended 
to intensify stem cell research in the interest of possible clinical benefits). This bill exemplifies 
recent attempts to facilitate genetic research.  Id.  But see H.R. 5269, 114th Cong. (2016) 
(exemplifying the intensity of opposition to genetic research). This bill would intend to 
nationally criminalize the destruction of a human embryos through in vitro fertilization or 
other purposes.  Id. 
97 See 142 Cong. Rec. 16,864, 16,869 (1996) (stating the potential scientific benefits from IVF 
and stem cell research known at the time). Representative Lowey mentions the potential for 
finding treatments or cures for various types of cancer and other diseases.  Id.  Speakers 
arguing for the adoption of the amendment also discuss their general intent to repeal the 
Dickey-Wicker Amendment.  Id. 
98 See id. (debating whether the federal government should fund research on human 
embryos). 
99 See id. (describing the Lowey Amendment as a replacement for the Dickey-Wicker 
Amendment, which did not come to fruition). 
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opposition to the Lowey Amendment won out, especially the repeated 
argument that taxpayer dollars should not go to the destruction of human 
embryos.100 
E. Current Landscape:  Developing Legal and Ethical Issues 
To paint a picture of where we stand with CRISPR now and what the 
road looks like going forward, three primary issues should be 
addressed.101  First, what type of funds are coming to CRISPR, and who 
controls that money?102  Second, with the Dickey-Wicker Amendment still 
in place, what are the ethical ramifications of that law today?103  Finally, 
with the recent amendments to NIH guidelines, how does it affect CRISPR 
moving forward?104 
Companies working with CRISPR have arisen in recent years that 
either receive private funding, are publicly traded, or both.105  This may 
lead some to believe that the issue of funding is resolved and that private 
funding is all that is necessary.106  However, institutions receiving only 
private funding rather than government grants have fewer restrictions 
and regulations to abide by.107  This is especially problematic with a highly 
                                                
100 See id. (stating the argument from then-Representative Coburn that life at such an early 
stage should not be destroyed). The arguments in support continually reiterate that the 
nature of the research to be funded would not destroy any embryos.  Id. 
101 See infra Part II.E (providing information on the current outlook for CRISPR relating to 
sources of funding, ethical concerns related to the Dickey-Wicker Amendment, and recent 
updates to the National Institutes of Health guidelines). 
102 See infra Part II.E (discussing the relevance of public and private funding in relation to 
research on CRISPR). 
103 See infra Part II.E (explaining current concerns about the Dickey-Wicker Amendment). 
104 See infra Part II.E (reporting recent changes to the NIH guidelines which open the door 
for CRISPR research). 
105 See The Intellia Therapeutics IPO—Editas vs. Intellia, NANALYZE (Apr. 18, 2016), 
http://www.nanalyze.com/2016/04/the-intellia-therapeutics-ipo-editas-vs-intellia/ 
[https://perma.cc/5SS9-UKBT] (discussing the initial public offerings (IPO) of Editas 
Medicine and Intellia Therapeutics). These two companies debuted their IPOs during the 
Spring of 2016 and recognize themselves as the future of gene-editing research.  Id.  After 
initially taking in nearly $150 million combined for their IPOs, the stocks have halted in 
growth.  Id.  This is likely due to the current patent litigation for CRISPR.  Cf. id. 
106 See generally id. (inferring that government funding could be seen as unnecessary in 
light of the hundreds of millions of dollars that companies have been raising and receiving 
from investors). 
107 See Anna Zaret, Editing Embryos: Considering Restrictions on Genetically Engineered 
Humans, 67 HASTINGS L.J. 1805, 1828–29 (2016) (proposing regulations on gene editing).  The 
author similarly proposes that laws such as the Dickey-Wicker Amendment prevent proper 
regulation of gene-editing technologies.  Id.  However, the author stresses the need for a 
committee to consider the ethical issues relating to different pieces of proposed legislation 
as well as a commissioned federal entity that would perform similar functions in facilitating 
gene-editing research.  Id.  Zaret’s proposal is similar in purpose to this Note, but focuses far 
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controversial technology like CRISPR, which many claim needs 
government oversight.108  With the Dickey-Wicker Amendment still in 
place, proper oversight and regulation cannot be implemented.109  Ethical 
guidelines on how research funds may be used are likely to be less 
stringent, because federal funding is not being provided.110 
At the peak of its relevancy, the Dickey-Wicker Amendment 
attempted to halt the cutting-edge, but ethically debatable, science of stem 
cell research.111  At this time in the mid 1990s, IVF was still controversial, 
and little was known about stem cell research, and the potential benefits 
of curing diseases were quite speculative.112  Twenty years later, these 
prospects are much more tangible.113  Not only are these benefits being 
realized in lab settings, but the ethical discussions have shifted due to a 
greater understanding of the science.114  The primary ethical concerns 
associated with CRISPR are no longer the destruction of embryos, but 
instead what changes could eventually be made to human embryos.115  
This shift not only signals that new issues must be addressed in the 
coming years, but also that the concerns addressed in the Dickey-Wicker 
Amendment are becoming increasingly irrelevant.116  Yet the law still 
exists and still bars federal funding for research that has advanced 
                                                
less on what institutions or government bodies may be required to address specific 
legislation, but rather a specific ethical framework itself that will be discussed below.  Id. 
108 See Genetically Engineered Human DNA: Hearing before the Subcomm. on Research and 
Technology of the H. Comm. on Science, Space, and Technology, 114th Cong. (2015) (statement of 
Jeffrey P. Kahn, Professor of Bioethics and Public Policy; Deputy Director for Policy and 
Administration, Berman Institute of Bioethics, Johns Hopkins University) (discussing 
current ethical frameworks in place, current ethical issues, and policy involving CRISPR and 
gene editing research). 
109 See Zaret, supra note 107 (discussing regulation and the Dickey-Wicker Amendment). 
110 See Collins, supra note 64 (explaining the negative implications of the Dickey-Wicker 
Amendment on CRISPR research). 
111 See 142 Cong. Rec. 16,864 (1996) (arguing the merits of the Dickey-Wicker Amendment 
against the alternative Lowey Amendment). 
112 See generally Sherley, 689 F.3d at 779 (noting the state of stem cell research in the mid 
1990s). “At the time of the adoption of the first Dickey-Wicker rider, scientists had not yet 
isolated embryonic stem cells (ESC), and the original enactment was apparently directed at 
another type of research performed on human embryos in the field of in vitro fertilization.”  
Id. 
113 See Susan Noakes, CRISPR Gene Editing Heads to Human Trial as Cancer Treatment, CBC 
NEWS (June 24, 2016), http://www.cbc.ca/news/health/human-trial-crispr-1.3651755 
[https://perma.cc/UXB9-Z2RT] (discussing approval by an NIH review board). Even 
though the clinical trial was approved, the study is privately funded by billionaire Sean 
Parker’s cancer foundation.  Id. 
114 See id. (expressing the promise of CRISPR to treat or cure diseases in the near future). 
115 See Regaledo, supra note 34 (acknowledging the power and capabilities of CRISPR). 
116 See generally Consolidated Appropriations Act of 2015, Pub. L. No. 114-113, 129 Stat. 
2242, 2283 (citing to the provisions of the Dickey-Wicker Amendment). 
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dramatically in recent years.117  The Dickey-Wicker Amendment’s likely 
unintended consequences are still ringing more than two decades later, 
and its language is outdated to a point of concern for the medical and 
scientific communities.118 
Rapidly-developing science may lead to rapidly-developing policy, 
and the NIH is no exception to this.119  In 2016, the NIH updated their 
guidelines to accommodate advancing research for CRISPR.120  In the 
same year, the NIH’s ethics panel approved a study involving the use of 
CRISPR in an attempt to cure a rare form of blindness.121  As of summer 
2016, no research institution has come forward to offer a home to this 
study and no start date had been announced.122  But new studies involving 
CRISPR are reported on at an increasingly higher rate.123  The NIH’s 
willingness to adapt to CRISPR is an encouraging sign, and a bump in 
investment of CRISPR may be on the horizon.124 
The House and Senate passed the 21st Century Cures Act, in late 
November and early December of 2016.125  This Act is a major bipartisan 
effort to fund and overhaul different aspects of the healthcare industry.126  
Parts of this bill encourage the investment in cancer research generally, 
and also provide enormous funding to the NIH.127  Some of these funds 
may theoretically find their way to CRISPR research, but it may be some 
                                                
117 See generally Collins, supra note 64 (acknowledging the problems still in place caused by 
the Dickey-Wicker Amendment). 
118 See id. (reiterating the concerns from the NIH director). 
119 See, e.g., id. (providing the NIH’s original stance on CRISPR). 
120 See Emerging Biotechnologies and the Role of the NIH RAC, NATIONAL INSTITUTES OF 
HEALTH (June 16, 2016), http://osp.od.nih.gov/under-the-poliscope/2016/06/emerging-
biotechnologies-and-role-nih-rac [https://perma.cc/NWF7-UXXF] (stating that the NIH 
would alter its grant guidelines in light of CRISPR developments). 
121 See Begley, supra note 42 (outlining the basic plan of the study). 
122 See Doudna, supra note 13, at 11:17 (calling for a temporary moratorium on embryonic 
CRISPR research).  See also Begley, supra note 42 (reporting the proposal put forward by 
researchers at the University of Pennsylvania).  Cf. Jacob Sherkow, Is CRISPR Patent Dispute 
Hurting Scientific Progress?, GENETIC LITERACY PROJECT (Apr. 19, 2016), 
https://www.geneticliteracyproject.org/2016/04/19/crispr-patent-dispute-hurting-
scientific-progress/ [https://perma.cc/5BWA-W66U] (discussing the CRISPR patent 
battle).  Research proposals have slowed and less research could take place before the 
conclusion of CRISPR’s patent dispute.  Id.   
123 Cf. Begley, supra note 42 (approving research aiming to cure genetic diseases). 
124 See generally id. (reporting on the NIH’s approval of a study using CRISPR).  Cf. 
Sherkow, supra note 122 (discussing the competing gene-editing companies). 
125 See Sherkow, supra note 122 (stating the bill’s history).  After three years of debate, both 
houses passed the bill with overwhelming support.  Id. 
126 See id. (discussing the act’s bipartisan support). 
127 See id. (stating the act’s inclusion of Vice President Biden’s “Moonshot”—an ambitious 
aim to cure cancer). 
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time before the direction of these new funds are realized.128  President 
Obama signed this act into law in December 2016.129  As explained below, 
new legislation should be introduced to address these numerous issues.130  
However, the more pertinent question is what approach is most 
appropriate to exploit the CRISPR technology and with what level of 
caution should our society approach it?131 
III.  ANALYSIS 
The co-inventor of CRISPR, Jennifer Doudna, has called for a 
worldwide “conversation” on how we should address the relevant ethical 
issues.132  Knowing what we do about CRISPR and its potential, as well as 
the law and policy surrounding gene editing, how our society addresses 
the relevant issues becomes the pressing question.133  Part III will attempt 
to accomplish two goals.134  First, Part III.A synthesizes the present issue 
that CRISPR raises in the United States.135  Second, Part III.B advocates for 
the best method to address these issues.136  The best way to remedy these 
issues is new legislation that will not only repeal past law that inhibits 
genetic research, but will also direct where federal funding for CRISPR 
research will go.137 
The Dickey-Wicker Amendment, which continues to be included in 
each year’s consolidated appropriations act, has led to some unintended 
consequences due to advances in genetics over the past two decades.138  
After some scientific advances with stem cell research, an executive order 
                                                
128 See id. (discussing how the act will take years to implement because the bill includes 
few deadlines and because it is over 1,000 pages long, among other reasons). 
129 See Associated Press, Obama Signs 21st Century Cures Act into Law, (Dec. 13, 2016), 
https://www.statnews.com/2016/12/13/21st-century-cures-obama-signs/ 
[https://perma.cc/C53E-2SGJ] (reflecting the quick passage of the act and subsequently 
being signed into law by President Obama). 
130 See infra Part III (calling for the introduction of a new federal legislation). 
131 See infra Part III (discussing various approaches to handling CRISPR’s ethical concerns 
through legislative and administrative means). 
132 See generally Doudna, supra note 13, at 11:17 (citing Jennifer Doudna on her position on 
a temporary halt to CRISPR’s use on embryos).  See also Abumrad & Krulwich, supra note 35 
(reiterating her stance on careful thought before proceeding with the editing of embryos). 
133 See infra Part III (balancing concerns with the benefits to our society of attempting to 
cure various genetic diseases). 
134 See infra Part III (addressing the ethical problems we face with CRISPR and how we 
may overcome such problems). 
135 See infra Part III.A (discussing the problem presented). 
136 See infra Part III.B (advocating for a particular solution). 
137 See infra Part III.B (detailing a solution through new legislation that can repeal old law 
while also directing research funds through ethical concerns). 
138 See Consolidated Appropriations Act, supra note 78 (citing to the Consolidated 
Appropriations Act of 2015, which includes the Dickey-Wicker Amendment). 
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from President Bush adapted the law to the science.139  Two years later, an 
executive order from President Obama similarly expanded the NIH’s 
ability to fund stem cell research to the extent of the law.140  On top of these 
two executive orders, the Sherley v. Sebelius court found that some 
language of the Dickey-Wicker Amendment was ambiguous.141  With a 
shift on the Supreme Court in 2017, it is unclear how such an 
interpretation might change, if at all.142  Only a few cases exist that could 
indicate Justice Gorsuch’s stance on a CRISPR issue relating to NIH 
                                                
139 See Sherley, 689 F.3d at 780 (citing to President George W. Bush’s 2007 executive order 
allowing for limited stem cell research). 
140 See id. (providing the language of President Obama’s 2009 executive order). 
141 See 689 F.3d at 780 (finding the word “research” to be ambiguous).  Currently, no case 
law exists on the issues of ethics, regulation, or funding for CRISPR.  Id.  The only case law 
relating to CRISPR at this early stage of development has been related to the CRISPR patent 
dispute.  See also Junior Party, No. 106,048 (referring to the case between the University of 
California and the Broad Institute).  This case covered the first patent dispute involving 
CRISPR.  Id.  Jennifer Doudna’s team at the University of California at Berkeley published 
their now-famous CRISPR study in 2012, which described the use of CRISPR in bacteria and 
the potential use of it in multicellular organisms.  Id.  Subsequently, the Broad Institute in 
Massachusetts published a study confirming CRISPR’s capabilities in multicellular 
organisms.  Id.  The California team submitted a non-expedited patent request before the 
Broad Institute; however, The Broad Institute’s patent request was expedited and approved.  
Id.  As a result, the California team’s patent was reviewed later and caused a patent 
interference, despite its earlier submission.  Id.  The court ruled that the California patent 
partially infringed the Broad Institute’s patent and that the California patent was restricted 
to technology relating only to CRISPR’s use in bacteria.  Id.  The ruling is thought by many 
to be a major blow to the California team in what is likely an emerging multi-billion-dollar 
industry.  Id.  Deborah Netburn, UC Berkeley Suffers Big Loss in CRISPR Patent Fight:  What's 
Next for the Powerful Gene-Editing Technology?, LOS ANGELES TIMES (Feb. 15, 2017), 
http://www.latimes.com/science/sciencenow/la-sci-sn-crispr-patent-decision-20170215-
story.html [https://perma.cc/BGG4-KPLL] (showing the likelihood of this case to go 
through multiple appeals before the dispute is completely resolved, which could likely take 
years). 
142 See Harry Enten & Oliver Roeder, Trump Picks Neil Gorsuch, A Scalia Clone, For The 
Supreme Court, FIVETHIRTYEIGHT (Jan 31, 2017), http://fivethirtyeight.com/features/neil-
gorsuch-supreme-court-trump/ [https://perma.cc/L72F-U5RA] (stating Judge Gorsuch’s 
“likelihood to invoke originalism in his opinions”).  See also Pino v. United States, 507 F.3d 
1233, 1238 (10th Cir. 2007) (certifying the question as to whether the Oklahoma Supreme 
Court should hear an appeal on wrongful death of an unviable fetus).  Judge Neil Gorsuch 
wrote the opinion certifying the question for the state court.  Id.  This case presented the 
question of whether a physician could be sued for wrongful death of a fetus that was 
unviable before medical treatment had been administered to the carrying mother.  Id.  
Gorsuch stated that the question was “precisely the sort that calls for us to seek authoritative 
guidance of the state supreme court.”  Id.  While this case only certified a question and did 
not decide the issue at hand, this case may loosely indicate where Gorsuch stands in similar 
cases that involve unviable embryos.  See generally id. (providing the most relevant opinion 
written by Gorsuch). 
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guidelines.143  This would indicate that a solution may be necessary that 
does not rely on whatever the current makeup of the Supreme Court is.144  
Former Chief Justice Burger once said the following: “[t]he law does not 
search out as do science and medicine; it reacts to social needs and 
demands.”145  The law has reacted to the science on this issue before, now 
it must be done again in a more conclusive manner.146 
Ethicists and scientists alike agree that the possibility of permanently 
editing the human germline (which would involve editing genes of viable 
human embryos) would be a dangerous and irreversible step for 
science.147  This is not to say that the issue could never be revisited at some 
point down the road.148  But the lack of understanding and experience we 
have for this powerful tool creates too many uncertainties and risks.149 
A. The Problem 
Part III.A discusses the Dickey-Wicker Amendment and why the ban 
on federal funding for embryonic research should be struck.150  This 
section also argues that law should be eliminated in order to make way 
for more modern legislation that properly addresses CRISPR’s ethical 
concerns.151  Clinical trials are underway using alternative gene-editing 
tools.152  In China, four clinical trials involving CRISPR have been 
announced and a study on human embryos has been conducted in the 
                                                
143 See Pino, 507 F.3d at 1238 (allowing the review of a wrongful death claim relating to an 
unviable fetus). 
144 See Enten & Roeder, supra note 142 (discussing Justice Gorsuch’s time on the 10th 
Circuit Court of Appeals in Denver and what can be drawn from his opinions). 
145 George P. Smith, II, Accessing Genomic Information or Safeguarding Genetic Privacy, 9 J.L. 
& Health 121, 133 (1994–1995) (quoting former Chief Justice of the United States Supreme 
Court Warren Burger). 
146 See infra Part IV (discussing the author’s proposal to fund and regulate CRISPR using 
the relevant ethical concerns as a guide). 
147 See, e.g., id. (exemplifying one leading argument to halt such research). 
148 See Regalado, supra note 34 (saying that if were are to attempt to permanently remove 
disease-causing genes from the human germline, editing embryos is the only known way of 
doing so). 
149 See, e.g., Begley, supra note 42 (reflecting the continuing improvement to CRISPR that 
need to be made without having risk of inaccurate genetic alterations to patients). 
150 See infra Part III.A (arguing that the Dickey-Wicker Amendment bans what is now safe 
and ethical work and is too broad for what more modern ethical concerns are). 
151 See infra Part III.A (setting out reasons for why the Dickey-Wicker Amendment is 
inadequate).  See also infra Part III.B (discussing various approaches to replacing the Dickey-
Wicker Amendment). 
152 See, e.g., Hultquist et al., A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies 
of HIV-Host Interactions in Primary Human T Cells, CELL PRESS (2016), 
http://www.sciencedirect.com/science/article/pii/S2211124716313365 
[https://perma.cc/94P5-GS2U] (summarizing a clinical trial using Zinc Finger Nucleases 
rather than CRISPR). 
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United States.153  In the United States, scientists are successfully editing 
human cell traits on a seemingly weekly basis in the lab.154  All signs 
suggest that it is only a matter of time before a treatment for one condition 
or another is discovered.155  Whether that occurs in the next year or further 
down the line, the United States should position itself to take advantage 
of such a discovery.156 
One reason this could be difficult is the Dickey-Wicker Amendment, 
the bill rider that prevents the alteration of a human embryo regardless of 
viability.157  This amendment needs to be altered or better yet eliminated 
and replaced to accommodate further research using CRISPR.158  Some of 
the greatest potential from CRISPR comes from studies that involve 
human embryos; however, when a law that makes such an act illegal, 
problems predictably arise.159  Studies on unviable human embryos are 
accepted among ethicists on a larger scale.160 
                                                
153 See NATIONAL INSTITUTES OF HEALTH, ClinicalTrials.gov, https://clinicaltrials.gov/ 
ct2/results?term=crispr [http://perma.cc/DF5Z-MUXH] (providing basic details about the 
four planned clinical trials in China).  See also Mullin, supra note 40 (reflecting the rapid 
progress of CRISPR research to the stages of studying it with human embryos). 
154 See, e.g., Sharon Begley, CRISPR Identifies Genes that Might be Targeted to Hobble HIV 
Infection, STAT (Oct. 25, 2016), https://www.statnews.com/2016/10/25/crispr-identifies-
hiv-genes/ [https://perma.cc/FZ5E-AWTS] (exemplifying research that has been 
conducted on the HIV virus as progress that has already occurred in early CRISPR studies). 
155 See generally Nanette Byrnes, A Big Bet That Gene Editing Will Cure Human Disease, MIT 
TECH. REV. (July 25, 2016), https://www.technologyreview.com/s/601846/a-big-bet-that-
gene-editing-will-cure-human-disease/ [https://perma.cc/9JJP-XZXY] (stating the 
confidence from newly-public Editas Medicine about their planned research with CRISPR 
and that the results will not disappoint). 
156 See generally id. (reiterating the confidence within Editas).  However, the technology to 
specifically attack many of these genetic diseases is still being developed.  Id. 
157 See, e.g., The Balanced Budget Downpayment Act of 1996, supra notes 65–66 
(exemplifying the language of the Dickey-Wicker Amendment in 2015’s Consolidated 
Appropriations Act). 
158 See generally id. (prohibiting harm to human embryos). 
159 See generally The Guardian’s View on Human Genome Editing: Find, Replace – and Cure, THE 
GUARDIAN (Sept. 2, 2015), https://www.theguardian.com/commentisfree/2015/sep/02/ 
the-guardian-view-on-human-genome-editing-find-replace-and-cure [https://perma.cc/ 
SZ5R-WX2N] (speaking to the benefits of permanently eliminating genetic mutations that 
cause diseases).  “Editing human embryos is categorically different to editing organs and 
other tissues. Genetic changes made to an embryo go on to affect all the cells in the adult.”  
Id. “That includes their sperm or eggs, so the changes are passed on to their children and all 
future generations.”  Id. 
160 See generally Rob Stein, Breaking Taboo, Swedish Scientist Seeks to Edit DNA of Healthy 
Human Embryos, NPR (Sept. 22, 2016), http://www.npr.org/sections/health-shots/ 
2016/09/22/494591738/breaking-taboo-swedish-scientist-seeks-to-edit-dna-of-healthy-
human-embryos [https://perma.cc/8MUG-QSDF] (recognizing the value of learning more 
about embryo development). 
Valparaiso University Law Review, Vol. 52, No. 3 [2018], Art. 3
https://scholar.valpo.edu/vulr/vol52/iss3/3
2018] CRISPR 527 
The Dickey-Wicker Amendment should be replaced because it no 
longer serves its original purpose.161  The law was intended to protect 
prenatal life at a time when in vitro fertilization research was progressing 
as a promising science itself.162  But, when a 20-year-old law infringes on 
further scientific research due to its broad language, changes are in 
order.163  While the NIH may have found a way around the amendment 
by approving a study, research that involves unviable human embryos is 
still legally dicey.164  This is because research on viable human embryos is 
still considered to be a dangerous road to go down, and research involving 
unviable embryos has reached a larger consensus of being permissible.165  
The Dickey-Wicker Amendment is still an imposing figure to those who 
aim to advance research in this area.166  This is because the Dickey-Wicker 
Amendment was directed toward concerns about the ethical nature of 
IVF, which has proven to be a safe, and now-common procedure.167  This 
                                                
161 See generally Megan Kearl, Dickey-Wicker Amendment, 1996, THE EMBRYO PROJECT 
ENCYCLOPEDIA (Aug. 27, 2010), https://embryo.asu.edu/pages/dickey-wicker-
amendment-1996 [https://perma.cc/A73E-EWDB] (noting the amendment’s creation in 
response to a push for embryonic research in light of in vitro fertilization).  The Dickey-
Wicker Amendment may have passed through Congress quickly because it was attached to 
an appropriations bill and the legislature had recently “come off two government 
shutdowns.”  Id.  See also Christopher Ingraham, Congressional Deadlock Has Doubled Since the 
1950s, WASH. P. (May 28, 2014), https://www.washingtonpost.com/news/wonk/wp/ 
2014/05/28/congressional-gridlock-has-doubled-since-the-1950s/ [https://perma.cc/ 
G24Y-6H8Y] (tracing the percentage of issues left unlegislated in a given year). “In 1947–
1948, fewer than thirty percent of issues were left unlegislated.”  Id.  “In 2011–2012, seventy-
one percent of issues were unlegislated.”  Id. 
162 See generally id. (determining later that stem cell research was not blocked by this 
amendment because it was sufficiently different from what the amendment banned). 
163  See generally Phillip K. Howard, The Crippling Hold of Old Law, THE WALL STREET 
JOURNAL (Apr. 1, 2016), http://www.wsj.com/articles/the-crippling-hold-of-old-law-
1459536718 [http://perma.cc/QCC3-JEMZ] (citing to a problem of “mountains of old 
statutes and regulations” as one reason why government has become so slow and clunky). 
164 See Begley, supra note 42 (stating that the NIH’s ethics committee approved a clinical 
trial after altering their grant guidelines, although the study has not yet been approved by 
the FDA). 
165 See Jad Abumrad & Robert Krulwich, The Primitive Streak, RADIOLAB (Sept. 23, 2016), 
http://www.radiolab.org/story/primitive-streak/ [https://perma.cc/M67W-6Y9L] 
(discussing the 13-day rule, which is used in embryonic stem-cell research).  The thirteen-
day rule provides that no research should be conducted on embryos once they reach thirteen 
days old.  Id.  Around the 13-day mark is when embryos begin to develop early human 
features where cells begin to differentiate.  Id.  At this time the embryo also begins to develop 
circulatory paths to connect to the womb in order obtain nutrients from the mother.  Id.  
Scientists have widely accepted this rule as the furthest one should study an embryo before 
ending the study and destroying the embryo.  Id. 
166 See generally Kearl, supra note 161 (describing the Dickey-Wicker Amendment as the 
sole barrier to further embryonic research). 
167 See Mailee R. Harris, Note, Stem Cells and The States: Promulgating Constitutional Bans on 
Embryonic Experimentation, 37 VAL. U. L. REV. 243–46 (2002) (providing statistics on IVF use).  
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federal ban should be struck to make way for the implementation of 
modern, forward-looking law that can adequately address the funding 
and regulation of CRISPR.168 
B. The Solution:  Current Bills and Proposed Approaches 
Others in the legal community agree that the first step to a solution 
involves repealing the Dickey-Wicker Amendment.169  However, there is 
disagreement on how to proceed after a successful repeal.170  Proposals 
range from an all-out ban on funding CRISPR, to others suggesting the 
forming of committees or expanding authority of the Food and Drug 
Administration.171  Part III.B critiques the effectiveness and plausibility of 
different approaches to regulate and fund CRISPR.172 
The impact of the 21st Century Cures Act on CRISPR cannot be fully 
understood at this point.173  One of the goals of the act is to take a more 
aggressive approach to cancer research.174  The act includes an investment 
                                                
In 2001, the number of frozen embryos for the purposes of IVF was at least 188,000.  Id. at 
245–46. 
168 See Zaret, supra note 107, at 1831 (recommending the elimination of the federal ban on 
funding embryonic research). 
169 See, e.g., id. (suggesting to lift the ban on embryonic research). 
170 See, e.g., id. (proposing a new federal agency similar to what is in place in the United 
Kingdom, called the Human Fertilisation and Embryology Authority (HFEA)).  The author 
continues by recognizing that lifting this ban would “open the door for regulatory 
framework” to be put in place.  Id.  This proposal follows with a three-step proposal for how 
to continue.  Id.  Others, meanwhile recognize that the Dickey-Wicker Amendment prohibits 
embryonic research funding by the government.  Sarah Ashley Barnett, Comment: Regulating 
Human Germline Modification in Light of CRISPR, 51 U. RICH. L. REV. 553, 576 (Jan. 2017). 
171 See Zaret, supra note 107, at 1828–31 (likening a potential agency to HFEA.  See also 
Barnett, supra note 170 (suggesting an expansion of the FDA); infra Part IV (providing this 
Note’s proposal).  The act would then direct funds to CRISPR research in four ways.  Id.  First, 
the language should focus funds to studies seeking to improve CRISPR itself and for human 
application in clinical trials.  Id.  Second, the legislation would bar research on viable human 
embryos.  Id.  We simply do not have enough information on the true ramifications of such 
an act and there is no agreement as to whether we should ever take that step.  Id.  Third, no 
funds will be provided to studies that seek to accomplish cosmetic goals such as changing a 
child’s eye color.  Id.  Additionally, using CRISPR in an agricultural setting is generally 
permitted, but is beyond the scope of this discussion.  Id.  Finally, if research institutions 
violate the guideline of using CRISPR on a viable human embryo, funding for that study will 
be revoked and future funding will be temporarily revoked.  Id. 
172 See infra Part III.B (analyzing approaches from various law review articles on their 
plausibility and effectiveness if pursued). 
173 See generally Obama Signs 21st Century Cures Act into Law, ASSOCIATED PRESS (Dec. 13, 
2016), https://www.statnews.com/2016/12/13/21st-century-cures-obama-signs/ 
[https://perma.cc/C53E-2SGJ] (showing how the act was only recently signed). 
174 See generally Weekly Address: Pass the 21st Century Cures Act, OFFICE OF THE PRESS 
SECRETARY (Dec. 3, 2016), https://www.whitehouse.gov/the-press-office/2016/12/03/ 
weekly-address-pass-21st-century-cures-act [https://perma.cc/66RJ-XY43] (stating the 
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in former Vice President Joe Biden’s Cancer Moonshot program.175  While 
research using CRISPR may see some of these funds, it is difficult to 
determine how much, if any at all, will go to CRISPR.176  Because CRISPR 
is not mentioned specifically in the act, a subsequent act may need to be 
implemented to assure adequate funding is being directed to CRISPR 
research.177  In the alternative, the implementation of the 21st Century 
Cures Act could be guided by the act proposed in this Note when it comes 
to directing research funding.178  This may be possible because the 21st 
Century Cures Act similarly empowers the National Institutes of Health 
in dispersing research grants.179  Ultimately, the 21st Century Cures Act 
does not detrimentally affect the act proposed in this Note, but reinforces 
the idea that investing in medical research is an issue susceptible to 
compromise in a divided Congress.180 
One offered proposal in the legal community to solve the ethical 
issues related to CRISPR is through a congressionally-established 
                                                
goals of the Act).  In President Obama’s weekly address, he set out the goals of the 21st 
Century Cures Act (also known as the Beau Biden Act) in a statement of support before the 
bill had been passed.  Id.  In addition to seeking out remedies to opioid addiction, the act 
aims to find cures for Alzheimer’s Disease and cancer generally.  Id. 
175 See generally id. (reiterating the goal for the United States to lead the charge in finding a 
cure for cancer).  The president goes on to emphasize how many diseases such as 
Alzheimer’s and Epilepsy touch so many lives and that it made compromise possible in this 
act.  Id. 
176 See Sheila Kaplan, Senate Passes Landmark 21st Century Cures Act—But It Will Take Years 
to Implement, STAT (Dec. 7, 2016), https://www.statnews.com/2016/12/07/21st-century-
cures-senate-passes/ [https://perma.cc/Q755-J6MR] (noting the lengthy process of 
implementing the 21st Century Cures Act).  However, the act will be difficult to implement 
and it may take a considerable amount of time to work out all of the details.  Id. 
[T]he Cures Act, nearly 1,000 pages long, does not lay out many 
deadlines.  The dirty secret is it’s going to take many years to implement 
these things,” said Bethany J. Hills, who runs the FDA practice at Mintz 
Levin Cohn Ferris Glovsky and Popeo. “There are many provisions 
requiring guidance, and whenever Congress has mandated that FDA 
provide guidance on something, the FDA historically is perpetually late. 
Id.  The FDA will require a lot of time to implement regulations for a lengthy bill such as this.  
Id. 
177 See H.R. 34-114, Dec. 8, 2016 (providing the language of the bill signed December 13, 
2016). 
178 See Regaledo, supra note 1 (discussing the ethical concerns related to CRISPR that 
should guide and direct the government funds to the appropriate research projects). 
179 See Kaplan, supra note 176 (discussing the effect of the 21st Century Cures Act on the 
National Institutes of Health).  The Act will increase the NIH’s budget by $4.8 billion.  Id.  
This also likely provides more certainty for the NIH with an incoming administration that 
presented numerous uncertainties about the organization’s future.  Id.  Cuts to both 
regulations and budgets send mixed messages.  See generally id. 
180 See Office of the Press Secretary, supra note 174 (providing President Obama’s statement 
describing the 21st Century Cures Act as one of compromise). 
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committee.181  This committee would attempt to accomplish two goals.182  
First, the committee would be in charge of considering ethical concerns 
related to specific CRISPR studies, obtain public opinion on the matter, 
and frame potential legislation.183  Such a committee may be useful in 
drafting the official legislation similar to the legislation being proposed in 
this Note.184  However, the formation of a committee would otherwise be 
unnecessary.185  Congressmen are largely qualified to intake public 
opinion from their constituents and to consider the relevant lawmaking 
process, but the same cannot be said for the ability to evaluate scientific 
proposals.186  The NIH is already equipped to do this, because they are the 
entity that approves and distributes grants for scientific and medical 
research.187  Specifically, the Recombinant DNA Advisory Committee 
(RAC) of the NIH approves clinical studies involving DNA (which would 
include CRISPR).188 
The second committee goal from this proposal would be to “consider 
the creation of a standing federal entity that would have authority over 
both public and private sectors” and would set standards for research.189  
Again, this is quite similar to functions carried out by the NIH.190  
Additionally, it is unlikely that the current political climate would allow 
                                                
181 See Zaret, supra note 107, at 1831 (proposing a Congressional committee that could sift 
through potential legislation as well as assist in establishing a new federal agency).  The 
formation of a committee could funnel policy through representatives and senators that have 
more expertise in science and medicine than the entire body of Congress.  Id. 
182 See id. (calling for a committee that would review legislation and possibly help in the 
formation of a new federal agency to handle CRISPR and all that comes with it). 
183 See id. (suggesting that this committee could serve as a filter for the drafts of proposed 
legislation coming in, not unlike the current committee system for bills). 
184 See generally id. (inferring that committees mark up legislation as part of the bill passage 
process in both houses of Congress, and a similar function would likely be performed here). 
185 See infra Part IV (stating why Congress should allow the NIH to make decisions about 
the ethical nature of each study within the boundaries set by lawmakers). 
186 See infra Part IV (noting how the NIH already has medical and ethical experts that make 
such considerations a part of the grant-awarding process). 
187 See generally NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid 
Molecules, NATIONAL INSTITUTES OF HEALTH (Apr. 2016), https://osp.od.nih.gov/wp-
content/uploads/2013/06/NIH_Guidelines.pdf [https://perma.cc/MHX3-ZSAF] 
(outlining safety considerations made by the NIH).  These guidelines apply to all research 
conducted in the United States.  Id. 
188 See id. (providing the lengthy list of guidelines reviewed by RAC). 
189 See Zaret, supra note 107, at 1832 (stating that Congress would lay out the ethical 
boundaries for this new agency).  The proposal in this Note specifies those ethical boundaries 
by stating which studies would be funded, which studies would not be funded, and the 
consequence for violating such ethical boundaries.  See also infra Part IV (providing a detailed 
proposal). 
190 See generally infra Part IV (contesting that the NIH is qualified for this task because it 
already deals with ethical oversight of genetic research). 
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for the creation of an entirely new federal agency.191  The new 
administration that took over in early 2017 has placed a high value on 
gutting agencies and cutting budgets across the board.192  The creation of 
a new federal agency would inevitably cause the creation of new 
government jobs.193  But, in a time where there may be a succession of 
government hiring freezes, it begins to look bleak that a new agency could 
be created.194  This is especially true for a potential agency that may 
overlap duties with the already-existing NIH.195  Instead, a piece of 
legislation that sets a government funding plan would have a higher 
likelihood of success.196  While budget cuts are currently being 
emphasized, the current administration has not ruled out shifting 
spending from one agency to another.197 
Another proposal to solve CRISPR-related issues is to introduce 
legislation that would expand or reinforce the Food and Drug 
Administration’s (FDA) role in regulating CRISPR.198  With or without 
new legislation, the FDA would be charged with the task of determining 
what clinical trials, treatments, or technologies would be safe for the 
public.199  The FDA does not explicitly cover CRISPR, and this may be 
                                                
191 See, e.g., Eric Krupke, How We Got Here: A Shutdown Timeline, NPR (Oct. 17, 2013), 
http://www.npr.org/sections/itsallpolitics/2013/10/16/235442199/how-we-got-here-a-
shutdown-timeline [https://perma.cc/G7FZ-ASY6] (chronicling the latest government 
shutdown). 
192 See, e.g., Glenn Thrush, Kate Kelly, and Maggie Haberman, Trump to Ask for Major Cuts 
to EPA, Increased Spending for Military, THE BOSTON GLOBE (Feb. 27, 2017), 
https://www.bostonglobe.com/news/politics/2017/02/26/trump-ask-for-major-cuts-
epa-increased-spending-for-military/bRLCI3ye7Ym0F4SNUNXo4H/story.html 
[https://perma.cc/2QA4-AAEG] (cutting the EPA’s budget by an estimated two-thirds). 
193 Cf. Presidential Memorandum Regarding the Hiring Freeze, THE WHITE HOUSE, OFFICE OF 
THE PRESS SECRETARY https://www.whitehouse.gov/the-press-office/2017/01/23/ 
presidential-memorandum-regarding-hiring-freeze [https://perma.cc/K9Q7-8HMJ] 
(analogizing that this would be off the table during a government hiring freeze). 
194 See, e.g., id. (stating that this hiring freeze extended to all executive agencies). 
195 See id. (inferring that a new agency is unlikely considering the memo states that the 
reduction of the government work force is sought to be made permanent through attrition). 
196 See infra Part IV (making the case for legislation that would allow for additional or fewer 
funds to be applied to CRISPR at set time periods). 
197 See Thrush, supra note 192 (“requesting tens of billions of dollars in reduction for the 
Environmental Protection Agency and State Department”). 
198 See Zaret, supra note 107 (noting the FDA’s “limited oversight” in this area currently).  
See also Barnett, supra note 170, at 580 (recommending the expansion of FDA oversight). 
199 See Consumer (Biologics), FDA (Sept. 18, 2013), https://www.fda.gov/ 
BiologicsBloodVaccines/ResourcesforYou/Consumers/default.htm [https://perma.cc/ 
D7NL-XZU8] (defining biologics as “biological products [that] include a wide range of 
products such as vaccines, blood and blood components, allergenics, somatic cells, gene 
therapy, tissues, and recombinant therapeutic proteins”).  CRISPR could fall under “gene 
therapies” in some instances.  Cf. id. (pointing out that CRISPR, as a new technology, could 
be categorized as different types of medical items). 
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because the potential uses for CRISPR are wide-ranging.200  This does raise 
interesting questions for how the FDA will classify CRISPR.201  Should the 
evaluation process for approval move forward as it does for biologics, 
treatments, medical devices, or as a new category altogether?202  While the 
FDA does have experience in this area, Congress’s focus should first be on 
the NIH.203  This is because the FDA will have nothing to approve if the 
studies and clinical trials are not occurring.204  Similarly, the NIH is a more 
effective body for preventing human germline editing before society is 
ready because they are the entity that sets guidelines for grant-receiving 
studies and would use those guidelines to direct government funds.205  
When it comes to privately-funded research, the FDA may have more 
control over whether such medical and genetic practices ever see the light 
of day.206  The legislation proposed in this Note deals exclusively with 
publicly-funded research for CRISPR.207  Additionally, it may be wise to 
begin considering regulatory approaches that directly addresses how 
intentional human germline editing would be approached.208  However, 
the use of CRISPR in adults and children to cure disease in single 
individuals is more pertinent at this time.209  This is because the emergence 
of clinical trials to accomplish just that in 2018 and beyond is pushing such 
uses of CRISPR from the theoretical realm into the practical.210 
                                                
200 See Zaret, supra note 107, at 1829 (stating that the FDA has jurisdiction over gene-editing 
procedure approval).  But see Barnett, supra note 170 (noting that the FDA does not have 
oversight over human germline editing).  This is because human germline editing is still 
banned in the United States.  Id. 
201 See Barnett, supra note 170, at 580 (realizing the different ways that CRISPR treatment 
could be classified when applying for FDA approval). 
202 See id. (bringing to light the fact that the CRISPR approval process by the FDA may 
differ based on the type of treatment). 
203 See (commenting on the FDA’s role in approving CRISPR experiments).  But see infra 
Part IV (recommending power be reinforced at the NIH and member institutions). 
204 See generally Zaret, supra note 107 (reflecting the FDA’s role in approving treatments 
that are theoretically ready for human application, which CRISPR is approaching in a limited 
sense). 
205 See generally NIH Guidelines, supra note 187 (covering all research, publicly funded or 
not, on the ethical and safety concerns of the NIH). 
206 Cf. NIH Guidelines, supra note 187 (referencing the distinct roles of the NIH and FDA 
when it comes to approving and using public funds for research, compared to approving a 
treatment or technology for human use). 
207 See infra Part IV (clarifying that NIH guidelines cover all relevant research conducted 
in the United States, but has more exclusive control over research receiving grants). 
208 See generally NAT. INST. OF HEALTH, supra note 21 (referencing the fast pace of genetic 
research, which would lead to a cause for forward-looking legislation beyond what is 
immediately at hand). 
209 See infra Part IV (arguing that an investment in public health and trying to cure 
debilitating diseases should be the force pushing this legislation through Congress). 
210 See Regaledo, supra note 1 (discussing the potential uses of CRISPR in 2017).  See also 
Mullin, supra note 40 (showing the direction of clinical trials). 
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Again, expansion of a federal agency seems unlikely under the current 
administration, but the redirection of funds may be more likely.211  It could 
be argued that legislation endorsing human germline editing would not 
gain enough support to be passed by Congress, and that would likely ring 
true at this time.212  However, the use of CRISPR in adults as well as other 
non-human-germline-editing methods raises fewer issues.213  This is 
especially true when the benefits are so tangible as compared to previous 
gene editing technologies which were slow and inaccurate.214 
As stated above, CRISPR presents multiple issues that must be 
confronted.215  Questions about ethics, previous legislative amendments, 
financial considerations, scientific progress, the multiple uses for CRISPR 
across medicine, agriculture, and pharmaceuticals pose a unique 
challenge.216  Introducing new legislation allows lawmakers to attack 
many, if not all, of these problems at once.217  This is because of the very 
nature of a legislative bill.218  Legislators are naturally positioned to work 
with policy and conflicting interests among citizens, business entities, and 
public institutions.219  Therefore, a bill introduced in the United States 
Congress would be the most logical and natural place to address 
                                                
211 See generally Krupke, supra note 191 (emphasizing how the additional cost of creating a 
new federal agency is not plausible at this point in time). 
212 See generally Zaret, supra note 107 (referring to questions about human germline editing 
in humans before the technology is perfected further). 
213 See, e.g., Chestnut, supra note 19 (comparing old gene-editing technologies such as 
TALENs to CRISPR, which adds promise through speed, affordability, and accuracy). 
214 See Kahn, supra note 44 (stating various ethical concerns in a Congressional hearing to 
the House Committee on Science, Space, and Technology).  Concerns are shared with many 
scientists and include frivolous uses as well as misuse in humans.  Id.  Such misuses at this 
point in time would include consent issues when permanently editing the genes of future 
generations that have not yet been conceived.  Id. 
215 See Regalado, supra note 34 (noting the debate for what humans should and should not 
use CRISPR). 
216 See Regalado, supra note 34 (reviewing the ethical concerns).  See also Skerrett, supra note 
49 (citing to the economic concerns associated with the cost of gene therapy using CRISPR).  
See also Maywa Montenegro, CRISPR is Coming to Agriculture – With Big Implications for Food, 
Farmers, Consumers, and Nature, ENSIA (Jan. 28, 2016), http://ensia.com/voices/crispr-is-
coming-to-agriculture-with-big-implications-for-food-farmers-consumers-and-nature/ 
[https://perma.cc/SD59-BSAR] (discussing the use of CRISPR in a variety of agricultural 
settings). 
217 See generally Introduction and Referral of Bills, UNITED STATES CONGRESS 
https://www.congress.gov/legislative-process/introduction-and-referral-of-bills 
[https://perma.cc/C5LP-QRQ3] (explaining the nature of introducing legislation as a bill). 
218 See generally id. (discussing the drafting of a bill’s language). 
219 See generally What is a Representative?, THE UNITED STATES HOUSE OF REPRESENTATIVES 
http://www.house.gov/content/learn/ [https://perma.cc/75BA-5U8D] (explaining how a 
member of the House of Representatives is meant to represent their constituents in their 
respective congressional district and advocate for their concerns). 
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CRISPR.220  Legislators are also in the unique position of answering to 
constituents.221  CRISPR’s ethical issues are ones that should require input 
from the public.222  Controversial ethical questions in science have never 
been ones in which our government decides for us.223  So if we are to 
conduct a true “worldwide conversation,” the United States’ decisions 
will carry considerable weight for the rest of the world.224  What legislators 
must do is determine the language of the legislation.225 
Comprehensive legislation is also a better avenue, because there is still 
progress to be made in CRISPR’s accuracy and overall potential, further 
research should be directed toward perfecting CRISPR.226  Eliminating the 
potential for problems in the human application of CRISPR is a necessary 
step to making this a treatment option a norm in medicine.227  Continuing 
progress in perfecting medical treatment should always be encouraged, 
but this is especially true for CRISPR, which is only four years old as a 
technological tool.228  Additionally, the prospect of curing or treating 
genetic diseases that have such a profound impact on our society is more 
likely to encourage compromise than many other issues that we face 
today.229  The combination of these issues should create an urgency and 
                                                
220 See id. (describing the position of a member of congress and their connection to their 
constituents).  See also infra Part IV (stating the importance of public input into a controversial 
issue such as CRISPR). 
221 See generally id. (commenting on a Congressman’s purpose to serve the people). 
222 See generally Doudna, supra note 13, at 11:17 (advocating for a public conversation 
among citizens and figures of authority in the fields of law, ethics, and science). 
223 See generally Emerging Biotechnologies and the Role of the NIH RAC, NATIONAL INSTITUTES 
OF HEALTH (June 16, 2016), http://osp.od.nih.gov/under-the-poliscope/2016/06/ 
emerging-biotechnologies-and-role-nih-rac [https://perma.cc/NWF7-UXXF] (announcing 
the altering of NIH guidelines that determine how research studies obtain grant funds from 
the NIH).  Even regulations go through a public comment period before being enacted.  See 
generally id. 
224 See generally Doudna, supra note 13, at 13:38 (implying that our society must come to 
some level of agreement on what acts are acceptable before proceeding with further research 
involving embryos). 
225 See Introduction and Referral of Bills, UNITED STATES CONGRESS (last visited June 18, 2017), 
https://www.congress.gov/legislative-process/introduction-and-referral-of-bills 
[https://perma.cc/C5LP-QRQ3] (noting the job of lawmakers and congressional lawyers to 
work on the specific language of a bill). 
226 See, e.g., Begley, supra note 154 (discussing CRISPR’s low degree of error, which still 
needs to be improved). 
227 See id. (noting the promise involved in one particular use of CRISPR). 
228 See id. (implying that the technology needs to improve its accuracy before application 
in humans). 
229 See generally NATIONAL INSTITUTES OF HEALTH https://www.genome.gov/ 
10001204/specific-genetic-disorders/ [https://perma.cc/BVF4-WEVP] (providing a non-
exhaustive list of many of the most common diseases that have a “genetic component”). 
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common purpose to accomplish the difficult issues presented by 
CRISPR.230 
One common thread from the proposals discussed above is that the 
regulation of CRISPR is discussed primarily as a way to curb potential 
harms from the technology’s development.231  The potential benefits of 
curing diseases with CRISPR do not go unrecognized by anyone.232  
However, regulation should not be seen purely as a barrier, but also as a 
facilitator.233  It is illogical that research would move forward without the 
relevant ethical concerns being sorted out for the long term with 
scheduled periods for reassessment.234  That is what this contribution aims 
to accomplish:  setting the table for legislation that serves as an ethical 
problem-solver and an enthusiastic endorsement for CRISPR research.235  
New legislation has the unique ability to perform this balancing act.236 
IV.  CONTRIBUTION 
This contribution is separated into two subsections.237  Part IV lays out 
the goals and intentions of the proposed legislation.238  Part IV also 
outlines repealing the Dickey-Wicker Amendment and then the ethical 
and scientific guidelines that will direct the NIH and individual research 
institutions in funding research on CRISPR.239  Part IV.B addresses a few 
                                                
230 See generally The Genetic Disease Foundation (GDF) Encourages Americans to Know Their 
Genes at KnowYourGenes.org in Observance of World Rare Disease Day, PR NEWSWIRE (Feb. 28, 
2010), http://www.prnewswire.com/news-releases/the-genetic-disease-foundation-gdf-
encourages-americans-to-know-their-genes-at-knowyourgenesorg-in-observance-of-world-
rare-disease-day-85763017.html [https://perma.cc/8QKQ-RBFW] (stating that over 12 
million individuals suffer from genetic diseases of various forms today in the United States). 
231 See Zaret, supra note 107, at 1832–38 (citing the primary downsides of regulation as 
politicizing science and the effects on procreative autonomy).  See also Barnett, supra note 170, 
at 581 (permitting the use of CRISPR, even in human germline editing).  This proposal sets 
the standards for approving CRISPR techniques but does not discuss government funding 
of such contributing research).  Id. 
232 See Barnett, supra note 170 (recognizing not only the benefits of CRISPR used on adults, 
but also the benefits of human germline editing when ethically sound). 
233 See infra Part IV (emphasizing the benefits to federal funding for CRISPR research, 
which would gain more support if regulations were put in place to satisfy the public’s 
concerns). 
234 See infra Part IV (proposing an approach that would allow for reassessment of human 
germline editing in the United States). 
235 See infra Part IV (laying out ethical boundaries to facilitate research and restrict 
unethical practices). 
236 See infra Part IV (proposing a two-goal piece of federal legislation). 
237 See infra Part IV (discussing the proposed legislation and then counterarguments). 
238 See infra Part IV (laying out what this proposed piece legislation hopes to accomplish, 
from repealing the Dickey-Wicker Amendment to implementing guidelines for how CRISPR 
research will be addressed in the short-term). 
239 See infra Part IV (outlining the proposition in terms of two larger parts). 
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arguments likely to be raised against this proposal.240  This subsection 
intends to differentiate and reason why this specific proposal would be 
more efficient and effective than alternative options.241 
In order to facilitate future research involving CRISPR, the ethical 
concerns must be addressed immediately.242  This can be done most 
efficiently through legislation passed by Congress with a primary goal of 
investing in public health.243  Keeping in mind the numerous potential 
uses for CRISPR, this Note will only focus on one aspect of this proposed 
act:  human application in a clinical trial setting.244  The scope of this 
legislation will therefore be tailored to the relevant ethical issues related 
to human application with the goal of curing and treating diseases and 
inherited genetic conditions.245 
A. The Act 
The first part of this act will repeal the Dickey-Wicker Amendment.246  
Second, to relieve concerns about the perceived dangers of living in a 
CRISPR world, this legislation should be narrowly tailored to achieve the 
goal of improving public health in America.247  That is why this legislation 
should fund two types of research involving CRISPR.248  Next, this 
legislation should direct funds that more directly achieve the goals of the 
legislation.249  More specifically, this act should fund research studies that 
                                                
240 See infra Part IV.B (addressing three counterarguments).  Specifically, the necessity for 
such legislation, the cost concerns, and the scope of the act.  Id.  See also Alison Peck, Re-
Framing Biotechnology Regulation, 72 FOOD & DRUG L.J. 314, 333, 339 (reflecting the growing 
need and support for new legislation on biotechnology). 
241 See infra Part IV.A (noting the unique advantages lawmakers have to address these 
many issues). 
242 See Kahn, supra note 44 (telling Congress the importance of resolving these ethical 
disputes is essential to realizing CRISPR’s full potential for medical patients). 
243 See UNITED STATES CONGRESS, supra note 225 (reiterating the flexibility in changing the 
law through legislation). 
244 See generally Regalado, supra note 34 (discussing the CRISPR landscape in the world of 
ethics). 
245 See NATIONAL INSTITUTES OF HEALTH, supra note 153 (providing information on three 
clinical trials scheduled in China). Clinical trials are taking place in China, but are 
progressing at a slower pace in the United States.  Id. 
246 See The Balanced Budget Downpayment Act of 1996, supra notes 65–66 (providing the 
broad language of the amendment). 
247 See generally Budget, NATIONAL INSTITUTES OF HEALTH (last visited June 3, 2017), 
https://www.nih.gov/about-nih/what-we-do/budget [https://perma.cc/P7AU-VHQA] 
(reflecting the $32.3 billion dollars the NIH invests in competitive grants each year).  That 
money from the consolidated appropriations act is the only funding coming from the 
American taxpayer.  Id. 
248 See, e.g., Begley, supra note 42 (exemplifying a clinical trial setting for research). 
249 See Zaret, supra note 107 (specifying that funding should be directed toward grants for 
research on CRISPR clinical trials). 
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intend to treat or cure genetically influenced diseases and conditions.250  
There will be no prioritization of which ailments should receive more or 
less attention through amount of funds or which studies will be funded 
earlier rather than later.251  The NIH and individual research institutions 
are far more qualified to make such determinations than lawmakers.252  
Accordingly, deference should be provided to the NIH and its member 
institutions.253  Further, this Note recommends that it should be made 
clear in the language of the bill that no ailment is too small to receive 
attention from CRISPR research.254  While the destructive nature of 
diseases such as Muscular Dystrophy and Alzheimer’s throughout our 
society is well-documented, it is not the job of the legislature to determine 
which populations of patients are in more or less need of aid.255  Similarly, 
lawmakers are largely unqualified to determine which ailments have the 
most hope of receiving a treatment or cure from CRISPR.256  This act is 
meant to empower the scientific community, not to step on its feet.257 
Next, this act would have to set guidelines for not only what types of 
studies would be included and excluded from eligibility for funding.258  It 
would also need to identify specific types of studies that would be 
prohibited whether the studies were receiving funding from this act or 
                                                
250 See, e.g., NAT. INST. OF HEALTH, supra note 153 (exemplifying different clinical trials in 
China planned to research various forms of cancer). 
251 See Doudna, supra note 13, at 7:53 (showing the promise of using CRISPR on diseases 
that affect the blood).  Jennifer Doudna believes that diseases of the blood will be researched 
heavily early on because of the higher level of access CRISPR has to blood cells.  Id.  She also 
believes that CRISPR therapies could arise within about ten years.  Id. 
252 See generally Understand NIH:  Finding the Right Fit for your Research, NATIONAL 
INSTITUTES OF HEALTH, http://grants.nih.gov/grants/understanding-nih.htm 
[https://perma.cc/K4YV-2J33] (introducing a background into the NIH’s grant program). 
253 See generally id. (emphasizing the NIH’s broad and deep history in determining a 
study’s fitness for grant funding).  See also Ben Merriman, “Editing”: A Productive Metaphor 
for Regulating CRISPR, 15 AM. J. OF BIOETHICS 62 (Dec. 2, 2015) (stating that “regulation is a 
metaphorical practice”).  “In most cases, regulation involves drawing an analogy between 
something new in science and something that is already regulated.”  Id. 
254 See generally NAT. INST. OF HEALTH https://www.genome.gov/10001204/specific-
genetic-disorders/ [https://perma.cc/BVF4-WEVP] (showing that the number of genetic 
diseases is large).  There is no legitimate way to differentiate between and prioritize treating 
one disease over another.  Id. 
255 See, e.g., HIV and AIDS in the United States of America, AVERT (updated July 22, 2016), 
http://www.avert.org/professionals/hiv-around-world/western-central-europe-north-
america/usa [https://perma.cc/2ARK-YMGW] (reflecting the 1.2 million people inflicted 
with HIV/AIDS in the United State in 2013). 
256 See Kahn, supra note 42 (stating that different groups need to come together to 
contribute in order to solve these problems). 
257 See Regaledo, supra note 244 (reiterating the intent of this proposal to facilitate research 
involving CRISPR to a greater degree). 
258 Cf. 81 Fed. Reg. 15,315 (Mar. 22, 2016) (Providing the language of the NIH’s newly 
adopted guidelines for awarding research grants). 
Hebert: Opening a Can of Genetically-Modified Worms: Funding and Regulati
Produced by The Berkeley Electronic Press, 2018
538 VALPARAISO UNIVERSITY LAW REVIEW [Vol. 52 
from private entities.259  Conducting research on viable human embryos 
would be entirely prohibited by this act until sufficient progress was made 
through research that a reassessment would be warranted.260 
As a final consideration, what consequences should be faced by those 
institutions that engage in research on what some would consider 
frivolous, or purely cosmetic uses of CRISPR?261  This would be addressed 
two-fold.262  First, institutions that use private funds to research CRISPR’s 
potential as a cosmetic tool would receive no penalty because no misuse 
of government funds occurred.263  Second, and most importantly, 
institutions that conduct research using CRISPR on viable human 
embryos would receive monetary sanctions and the research project 
would be terminated.264  This is arguably a harsh penalty for an institution 
not partaking in the use of government funds directly.265  However, one 
of the central purposes of this legislation is to dissuade and prevent 
research that could result in irreparable harm and is still considered to be 
unethical by some.266  If institutions that apply for funds with outward 
intentions that meet the above criteria, but in fact use the funds to study a 
non-included purpose of CRISPR, possible sanctions could be enforced.267  
This does not appear to be a significant concern at the present time, but 
the institution would likely have their funding revoked, and would be 
reviewed further according to NIH guidelines.268 
                                                
259 See Intellia, supra note 27 (discussing two companies competing to use CRISPR in 
clinical trials). 
260 See generally Abumrad & Krulwich, supra note 35 (moving in the direction of Jennifer 
Doudna’s proposal that we should not be editing viable human embryos until we know 
much more about the process, and after coming to a societal consensus on how far we should 
go with gene editing). 
261 See, e.g., Abumrad & Krulwich, supra note 35 (discussing the theoretical possibility of 
turning a Chihuahua into a Great Dane by using CRISPR). 
262 See supra Part IV (breaking down the contribution’s proposal into two parts). 
263 See, e.g., Intellia, supra note 25 (exemplifying a company that will be using CRISPR in 
various settings).  Intellia was founded by co-inventor of CRISPR, Jennifer Doudna.  Cf. id.  
Intellia made its initial public offering (IPO) earlier in 2016.  Id.  See also Editas, supra note 25 
(adding more information about the company’s goals in using CRISPR). 
264 See, e.g., Begley, supra note 42 (exemplifying an institution that could theoretically be 
penalized in such manner).  Although the University of Pennsylvania has not been awarded 
the distinction of housing this study, researchers from the university were the ones that 
received approval from the NIH.  Id. 
265 Cf. Collins, supra note 64 (stating a necessity to combat the ethical concerns held by 
many; without repercussions, oversight is less likely to be taken seriously). 
266 See Doudna, supra note 13, at 11:55 (raising concerns about whether our society is ready 
for human germline editing). 
267 See, e.g., Abumrad & Krulwich, supra note 35 (using examples such as changing the 
species of a dog or raising extinct species of animals like the wooly mammoth). 
268 See generally Begley, supra note 42 (describing the first clinical trial application to be 
approved). 
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B. Commentary 
Many may argue that this act would be unnecessary because the NIH 
has already amended their guidelines to accommodate CRISPR.269 Indeed, 
the NIH amended their guidelines in 2015 after previously suggesting it 
would not do so.270  However, this act is not simply a directive to the 
NIH.271  It is instead Congress taking considerations on how a 
controversial piece of technology will be handled by independent research 
institutes.272  How research institutes will handle ethical considerations as 
well as what types of studies will be funded by the NIH, and deciding 
what types of studies will still be impermissible with private funding 
remain critical issues.273  Studies are becoming more common, and 
scientists have been successful in altering traits in human cells.274  It seems 
to be only a matter of time before treatments and cures are on the 
horizon.275  Therefore, a legislative plan should be put in place for making 
such medical treatments affordable and available.276 
The national debt and the use of taxpayer money are hot issues in 
today’s politics.277  In turn, both issues have been considered in the 
formation of this proposal.278  There is tremendous research on the 
monetary cost of a mentally and physically unhealthy population in 
America.279  This act is certainly not capable of curing the country’s 
numerous ailments overnight, but as a long-term investment, an act like 
                                                
269 See 81 Fed. Reg. 15,315 (Mar. 22, 2016) (reflecting the recent amendments to the NIH 
guidelines which were implemented in order to accommodate CRISPR). 
270 See Collins, supra note 64 (stating that the NIH has no intention to become involved with 
gene editing at any point in the near future). 
271 See NAT. INST. OF HEALTH, supra note 245 (reiterating the true purpose of the proposed 
act). 
272 See id. (putting trust in Congress partly because of its unique relationship with the 
American people, who should be providing their input on this issue). 
273 See generally Understand NIH, supra note 252 (showing the task set out the NIH and the 
NIH’s partner institutions of determining which studies will receive federal research grants 
from the NIH). 
274 See, e.g., Begley, supra note 154 (discussing progress in a study researching Sickle Cell 
in mice). 
275 See generally Begley, supra note 42 (discussing the steps being taken to take CRISPR to 
human trials). 
276 See Skerrett, supra note 49 (reflecting concern about CRISPR treatments becoming 
available to only the wealthy). 
277 See Jake Miller, Issue Brief: Debt and Deficit, CBS NEWS (October 1, 2012), 
http://www.cbsnews.com/news/issue-brief-debt-and-deficit/ [https://perma.cc/H3PD-
L5KA] (highlighting concerns about mandatory spending contributing toward the deficit). 
278 Cf. NIH, supra note 247 (noting that the NIH receives about $31 billion in funding 
annually). 
279 See, e.g., MAYO CLINIC HEALTH SOLUTIONS http://www.tcyh.org/employers/ 
downloads/Extra_MayoCostOfHealth.pdf [https://perma.cc/XB8S-V6DU] (stating that 
employee illness cost employers $47 billion in productivity loss). 
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this has the potential to put more money in the pockets of citizens.280  A 
healthier population logically leads to a healthier and more vibrant 
economy at the cost of a short-term investment.281 
One might criticize this proposal as one that comes woefully short of 
addressing all of the relevant issues faced with CRISPR, and that 
individual would not be wrong in saying so.282  The ethical issues are 
numerous, the uncertainty in the technology remains, and the potentially 
beneficial uses of CRISPR grow by the day.283  However, the issues this 
proposed legislation raises and attempts to remedy are narrow.284  Ideally, 
similar narrowly-tailored acts would follow to address concerns raised in 
other fields such as animal rights, world hunger, and agriculture.285  But 
this act is intended as a remedy to the ailments of public health, and 
CRISPR is better positioned to accomplish that goal than any other 
scientific discovery of our time.286 
V.  CONCLUSION  
After the advent of CRISPR/Cas9, the scientific community is 
clamoring not only about CRISPR’s medical potential, but also the 
emanating ethical concerns.  Some fear that editing the human germline is 
dangerous.  These types of changes to viable human embryos will be 
passed down to later generations.  There are also concerns about where 
the technology is right now.  There is still progress to be made in accuracy 
and reliability before CRISPR can be used on humans on a large scale.  
Others, however, are more concerned about challenges to be faced further 
down the road such as keeping gene therapy costs low or having too much 
control over the genes of our children. 
                                                
280 See generally Anna Louise Sussman, Burden of Healthcare Costs Shifting to the Middle Class, 
WALL ST. J. (Aug. 25, 2016), http://www.wsj.com/articles/burden-of-health-care-costs-
moves-to-the-middle-class-1472166246 [https://perma.cc/KK94-H65H] (noting the rapidly 
increasing healthcare costs for Americans, partly caused by health conditions). 
281 See generally id. (reflecting the increasing amounts of money Americans are spending on 
health care). 
282 See Regalado, supra note 34 (discussing the numerous issues with CRISPR that are not 
directly addressed here). 
283 See, e.g., Begley, supra note 248 (exemplifying the continuing progress for treating 
diseases of the blood with CRISPR).  The article also notes that the technology is still being 
perfected as it still has the potential for unintended genetic mutations.  Id.  “The errors 
occurred in less than 0.10 percent of the cells tested, which is still a concerning number.”  Id. 
284 See supra note 181 (reiterating the focus of this proposal on the investment in funding 
for clinical trials for CRISPR while other uses for CRISPR may be just as valid). 
285 See generally Zaret, supra note 107 (proposing the introduction of a committee that 
would sift through different bills pertaining to CRISPR). 
286 See Chestnut, supra note 19 (discussing the overall purpose of this proposed act to be a 
step toward curing and treating genetic diseases). 
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The quickly advancing science surrounding CRISPR is outpacing the 
relevant law by years, even decades.  The Dickey-Wicker Amendment 
remains as an obstacle for researchers that want to study CRISPR in 
human embryos.  These problems are most efficiently remedied by new 
legislation introduced and enacted by Congress.  Such legislation would 
not only provide and direct funds to be utilized for research on CRISPR, 
but it would also address many of the related ethical concerns.  Congress 
should introduce a bill that repeals the Dickey-Wicker Amendment. 
Such a unifying cause, such as genetic illnesses, is sufficient reason to 
come to a compromise on how to fully take advantage of this truly 
revolutionary technology.  Jennifer Doudna has called for a “worldwide 
conversation” on the ethical considerations of CRISPR.  The purpose of 
which is that we, as a society, should decide what steps we are willing to 
take to achieve such desired goals as curing and treating genetic disease.  
The scientific community has come to a consensus on CRISPR’s benefits; 
now it is time for lawmakers and our community as a whole to ensure that 
this powerful tool will be utilized effectively and responsibly for the years 
to come. 
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